β2-adrenergic signaling controls neonatal respiratory syncytial virus infection by promoting viral clearance and airway protection Authors: Sandeep Adhikari, Camille Carrier, Prabhu Raj Joshi, Pankaj Baral Published: 2025 ABSTRACT Respiratory syncytial virus (RSV) is the most common cause of acute bronchiolitis and pneumonia in children under 5 years of age. RSV infection is characterized by lung inflammation, viral expansion, and airway barrier destruction. The crosstalk between neurons and immune and non-immune cells develops from early life onwards. The lungs and airways are densely innervated by sympathetic neurons where they secrete the neurotransmitter noradrenaline (NA) at homeostasis and following injury in adult mice. NA, once secreted into the lungs, can act on immune and non-immune cells through β-adrenergic receptors (β-ARs). However, it is unknown whether NA-β-AR signaling axis regulates antiviral immunity during early-life infections. In a mouse model of neonatal RSV infection, we find that stimulation of adrenergic signaling via β2-AR agonist increases viral clearance, anti-inflammatory responses, and disease recovery. By contrast, loss of sympathetic neurons and β2-AR increases the RSV viral load and immunopathology in neonates. Stimulating β2-AR signaling has several downstream effects, including reduced airway mucus secretion and protection from endothelial barrier disruption, which together prevent airway blockade, respiratory failure, and facilitate control of RSV infection. Collectively, our studies demonstrate that sympathetic neurons and β2-AR signaling protect neonates from viral expansion and lung barrier breakdown, promoting antiviral defense. Introduction Respiratory viral infections are the most common cause of morbidity and mortality among children under 5 years old, affecting millions of lives globally1,2. Respiratory syncytial virus (RSV), a non-segmented single-stranded RNA virus, is the most common cause of bronchiolitis and viral pneumonia in infants and young children3,4. In 2019, 33 million RSV-associated cases and >100,000 RSV-associated deaths were estimated worldwide3. RSV infection causes illnesses ranging from mild to severe diseases caused by viral factors and host responses5. Upon infection, RSV first binds to epithelium of the upper respiratory tract. During later stages of infection, RSV can cause severe lung damage and obstruction of the airways due to barrier destruction, uncontrolled mucus production, and immune infiltration6–9. RSV infection severely affects lower respiratory tract in newborns and cause viral pneumonia. Current clinical approaches include antibody-based prophylaxis such as Palivizumab and Nirsevimab, or supportive antiviral treatments post-infection10,11. Recently approved maternal vaccine provide an active immunization in pregnant mothers and protection to infants. However, all available vaccines provide only short-term protection to infants and children and cannot prevent from reinfections. Thus, there is a need of better understanding of the pathogenesis of RSV infection and development of therapies for infected newborn and infant patients. The airways and lungs are densely innervated by sympathetic neurons, which mediate stress signaling and bronchomodulation. These neurons secrete the neurotransmitter noradrenaline (NA) from nerve terminals, which has pleiotropic effects on multiple lung cell-types during homeostasis, inflammation and injury12–16. NA can act on β-adrenergic receptors (β-ARs) expressed on airway smooth muscle cells to drive bronchodilation, and on immune cells to suppress cytokine production17. While such studies have been mainly conducted in adult animals, it is unknown whether the sympathetic neurons and signaling to β-AR modulate lung inflammation in neonates and impact the host response to RSV infection. A key aspect of successful respiratory defense to infection is induction of host tolerance mechanisms to prevent immunopathology and barrier destruction. One of the first host responses after respiratory RSV infection is viral recognition by TLR4/7/8, RIG-I and other recognition pathways that mediate the antiviral responses, which leads to induction of interferon (IFN) production and RSV-specific CD8+ T cells to promote viral clearance9,18. However, RSV-infection can also drive increased pulmonary neutrophils and increased levels of TNF-α, IL6, and CXCL-1 that cause immunopathology and mortality6,9,19. Thus, an effective antiviral host response against RSV requires both promotion of viral clearance and regulation of harmful immunopathology and barrier destruction. Tissue-reparative macrophages, antiviral monocytes, anti-inflammatory factors (e.g., IL-10), and functional endothelial cells (ECs) can promote tolerance and barrier protection9. Alveolar ECs & lung-resident macrophages (alveolar and interstitial macrophages) express high levels of β2-adernergic receptor20,21. We hypothesized that activation of β2-adernergic receptors on these cells might provide lung protection from endothelial barrier disruption and immunopathology during RSV infection. Upon activation, β2-AR signals via Gs-based induction of cAMP and PKA to drive immunomodulation by suppressing cytokine levels and other transcriptional changes. The β2-agonists (albuterol, salmeterol) are FDA approved drugs and have been used for the treatment of asthma and COPD by enhancing bronchodilation and easing breathing22. Previous work has shown that β2-agonists in adult mice suppress type 2 inflammation and anti-helminth immunity via suppression of type 2 innate lymphoid cell responses in the lung23. However, it is less understood if β2-agonists can alter the lung damage and host defense against viral infection. It is also unknown if β2-AR signaling promotes antiviral cytokine production (e.g., IFN pathways) and viral clearance, nor barrier protection and disease recovery in the setting of RSV-infection in neonates. While the revised 2014 American Academy of Pediatrics guidelines suggest β2-agonist treatment can provide transient breathing relieve in infants with RSV-induced bronchiolitis like it does for asthma and COPD patients, the updated guidance recommends against its use because of no clear benefit in recovery and length of hospital stay among infected patients in clinical studies24,25. However, few clinical studies also suggest that β2-agonist use might be helpful in some cases, and further in-depth studies are needed to determine the subgroups among children by considering factors such as age group, family history, immune parameters, previous exposure to disease, and/or time extent of bronchodilator use25–27. Importantly, there is a knowledge gap in clinical studies whether β2 agonist can alter lung immune cell dynamics, airway inflammation, and viral clearance during RSV infection. Our study is significant as it aims to fill these gaps. We here found that the local β2-AR agonist (albuterol) treatment in RSV-infected neonatal mice decreased morbidity and lung pathology. By contrast, depletion of sympathetic neurons and β2-AR deficiency resulted in enhanced immunopathology and RSV load. Mechanistically, β2-AR signaling increases interstitial macrophage abundance, type III interferon (IFN-λ2) production, barrier maintenance, and viral clearance. Thus, our data indicate a potential beneficial role of sympathetic neurons and β2-AR signaling in promoting airway protection to RSV infection. Results Local administration of β2-adrenergic receptor agonist limits RSV-induced morbidity in neonates We first investigated whether treating neonatal mice with a β2-agonist alters their host response against RSV. To address this question, we first established a non-lethal neonatal RSV infection model in postnatal day 7 (P7) pups of C57BL/6J mice28. In this model, P7 pups were intranasally infected with 1.6 ×106 TCID50/10 µL (5 µL per nostril) of RSV or with vehicle (mock inoculation), followed by daily measurements of body weight of pups until 14 days post-infection (dpi). To determine the therapeutic efficacy of β2-agonist, we intranasally inoculated two doses of albuterol (5 µg/10 µL/neonate) or PBS at 2 and 5 dpi (Fig. 1A). While all neonatal groups gained weight as previously shown28,29, RSV-infected neonates showed a mark reduction in body weight gain starting from 1 dpi until 14 dpi as compared to the percentage weight gain in mock-inoculated group (the average difference reached >35% at 7dpi and >56% at 14dpi) (Fig. 1B, C). We observed a significant increase in percentage weight gain in albuterol-treated group as compared to percentage weight gain in PBS-treated group at 3-9 dpi and 13-14 dpi, suggesting that the local albuterol treatment is reducing the morbidity of RSV-infected neonates (Fig. 1C). From 3-7 dpi, the increase in body weight gain in albuterol-treated RSV-infected neonates compared to the percentage body weight gain in PBS-treated infected mice was observed to be >10% on average. By contrast, there were no significant differences in body weight gain between mock-inoculated neonates treated with PBS and albuterol at any time point between 1-14 days post-inoculation, suggesting albuterol itself is not having an impact on the overall physiology of the neonates (Fig. 1B). Further, we did not find a significant difference in actual measured body weight (g) between PBS- and albuterol-treated P7 neonates at day 0 of inoculation for both mock- and RSV-inoculated groups (Supplementary Fig. 1), indicating enhanced recovery of RSV-infected neonates with β2-agonist treatment was not due to increased body weight before inoculation of β2-agonist and RSV. Upon UV-inactivated RSV virus challenge (1.6 ×106 TCID50 per neonate), there was no difference in body weight gain between PBS-and albuterol-treated neonates at any time point up to 14 days post-challenge (Fig. 1D), suggesting the β2-agonist-mediated host protection might involve RSV replication control mechanism in the infected lungs. Also, we did not find a difference in actual measured body weight (g) among P7 PBS- and albuterol-treated neonates at day 0 of UV-inactivated RSV challenge (Supplementary Fig. 1). In sum, our data suggest that the intranasal treatment of β2-agonist restricts disease morbidity in RSV-infected neonates.Fig. 1Local administration of β2-adrenergic agonist limits RSV-induced morbidity in neonates.A Schematic showing C57BL/6 J post-natal day 7 (P7) neonates were intranasally (i.n.) inoculated with mock or RSV (1.6 ×106 TCID50/10 μL per neonate). At 2- and 5-days post-inoculation, neonates were treated with albuterol (β2-agonist, 5 μg/mouse) or PBS intranasally. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/nt1igsc. B Mock-inoculated group of mice received only sterile 1X PBS or albuterol. Weight change difference between PBS- and albuterol-treated neonates in percentage original weight scale on the Y-axis for 14-day post-inoculations (till P21). C Weight change difference between PBS- and albuterol-treated neonates after RSV infection for 14 dpi (till P21). n = 12 (mock-PBS), n = 9 (mock-albuterol), n = 13 (Live RSV-PBS), and n = 14 (Live RSV-albuterol) mice (males and females) were used, data from 1-3 experiments (B, C). D The percent original weight change difference between PBS- and albuterol-treated neonates after UV-inactivated RSV (1.6 ×106 TCID50 per neonate) challenge over the 14-days post-challenge period (till P21). n = 9 (PBS) and n = 7 (albuterol) mice (males and females combined) were used, data from 1 experiment. Two-way repeated measure ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. Data in (B)–(D) are presented as mean ± SEM. *P < 0.05, **P < 0.01, ns = not significant. Exact p-values are included in the source data file. Local administration of β2-adrenergic agonist limits RSV-induced morbidity in neonates. A Schematic showing C57BL/6 J post-natal day 7 (P7) neonates were intranasally (i.n.) inoculated with mock or RSV (1.6 ×106 TCID50/10 μL per neonate). At 2- and 5-days post-inoculation, neonates were treated with albuterol (β2-agonist, 5 μg/mouse) or PBS intranasally. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/nt1igsc. B Mock-inoculated group of mice received only sterile 1X PBS or albuterol. Weight change difference between PBS- and albuterol-treated neonates in percentage original weight scale on the Y-axis for 14-day post-inoculations (till P21). C Weight change difference between PBS- and albuterol-treated neonates after RSV infection for 14 dpi (till P21). n = 12 (mock-PBS), n = 9 (mock-albuterol), n = 13 (Live RSV-PBS), and n = 14 (Live RSV-albuterol) mice (males and females) were used, data from 1-3 experiments (B, C). D The percent original weight change difference between PBS- and albuterol-treated neonates after UV-inactivated RSV (1.6 ×106 TCID50 per neonate) challenge over the 14-days post-challenge period (till P21). n = 9 (PBS) and n = 7 (albuterol) mice (males and females combined) were used, data from 1 experiment. Two-way repeated measure ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. Data in (B)–(D) are presented as mean ± SEM. *P < 0.05, **P < 0.01, ns = not significant. Exact p-values are included in the source data file. β2-agonist treatment protects neonates from RSV-induced immunopathology Previous studies have shown that RSV infection causes lung damage that is associated with peribronchial and perivascular inflammatory cellular infiltration6,8,30. We next asked if β2-agonist treatment reduces RSV-induced immunopathology in neonates and contributes to disease recovery of infected mice. To assess lung pathology, we performed morphometric analyses of Hematoxylin and Eosin (H&E)-stained lung sections of albuterol-and PBS-treated neonates after days 7 RSV or mock inoculation, a time point where we observed significant difference in body weight gain. In mock-inoculated neonates, we did not observe differences in lung tissues, alveolar structures and cellular infiltration between albuterol-treated and PBS-treated groups (Fig. 2A–C, Supplementary Fig. 2). RSV-inoculated PBS-treated mice showed significant lung damage as judged by increased cellular influx, airway collapse, and red blood cell (RBC) accumulation (Fig. 2A, B, Supplementary Fig. 2), confirming that the RSV infection causes immunopathology in neonates. By contrast, we observed a significant amelioration of lung damage in RSV-infected neonates treated with β2-agonist (albuterol) by histopathological analyses of lung sections and histology scoring(Fig. 2B, C, Supplementary Fig. 2). In particular, RSV-induced RBC accumulation in the airspaces and airway collapse were found to be significantly lower in the lungs of albuterol-treated neonates when compared to the lungs of PBS-treated neonates (Fig. 2B, C). These data indicate that the β2-AR stimulation has a beneficial impact in limiting lung inflammation and airway barrier disruption in RSV-infected neonates.Fig. 2Treatment of neonates with β2-agonist restricts RSV-induced immunopathology.P7 neonates were infected with RSV with 1.6 ×106 TCID50/10 μL per neonate and then treated with albuterol (5 μg/mouse) or PBS intranasally at 2 and 5 dpi. The whole lungs were collected at 7 dpi for Hematoxylin and Eosin (H&E) staining. PBS and albuterol were also treated for the mock-inoculated group of mice as controls. A Representative 1X magnification of H&E-stained lung section images from 1 to 2 experiments with similar results. Scale bar, 3 mm. B Representative 20X magnification of 1X lung section images (shown in rectangles), showing the severity of immunopathology and airway collapses. The black arrows indicate RBC accumulation around the airways. Scale bar, 200 μm. C Quantitative scoring of lung pathology. Sample size of PBS-treated (mock) n = 7 mice, albuterol-treated (mock) n = 4 mice, PBS-treated (RSV) n = 5 mice, and albuterol-treated (RSV) n = 6 mice were used, data from 1 to 2 experiments. Data are shown in mean ± SEM. An Ordinary Two-way ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. *P < 0.05, ***P < 0.001, ****P < 0.0001. Exact p-values are included in the source data file. Treatment of neonates with β2-agonist restricts RSV-induced immunopathology. P7 neonates were infected with RSV with 1.6 ×106 TCID50/10 μL per neonate and then treated with albuterol (5 μg/mouse) or PBS intranasally at 2 and 5 dpi. The whole lungs were collected at 7 dpi for Hematoxylin and Eosin (H&E) staining. PBS and albuterol were also treated for the mock-inoculated group of mice as controls. A Representative 1X magnification of H&E-stained lung section images from 1 to 2 experiments with similar results. Scale bar, 3 mm. B Representative 20X magnification of 1X lung section images (shown in rectangles), showing the severity of immunopathology and airway collapses. The black arrows indicate RBC accumulation around the airways. Scale bar, 200 μm. C Quantitative scoring of lung pathology. Sample size of PBS-treated (mock) n = 7 mice, albuterol-treated (mock) n = 4 mice, PBS-treated (RSV) n = 5 mice, and albuterol-treated (RSV) n = 6 mice were used, data from 1 to 2 experiments. Data are shown in mean ± SEM. An Ordinary Two-way ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. *P < 0.05, ***P < 0.001, ****P < 0.0001. Exact p-values are included in the source data file. Another hallmark of lung pathology during RSV infection is increased pro-inflammatory cytokine and chemokine production7,9,31. Previous studies have demonstrated a positive correlation of disease severity with elevated levels of inflammatory cytokines in RSV infections31–33. We next examined expression of pro-inflammatory cytokines and chemokines with and without β2-agonist treatment. We found a significant reduction in the transcript levels of Il6, Cxcl1 and Il1b mRNA at 7 dpi in the lungs of albuterol-treated mice when compared to the levels in the lungs of PBS-treated mice (Fig. 3A). Baseline expression levels of Il6, Cxcl1 and Il1b in PBS-and albuterol-treated lungs did not show any significant differences in the mock groups (Fig. 3A). Using a LEGENDPlex inflammatory cytokine panel to detect protein levels of cytokines, we found that β2-agonist treatment suppressed the levels of IL-1β, IL-6, and CXCL-1 in RSV-infected mice (Fig. 3B). We also examined the levels of Th2 cytokines (IL-4, IL-5 and IL-13) in lung homogenates from RSV-infected neonates. A significant reduction in the level of IL-13 in albuterol-treated neonates at 7 dpi was found as compared to the level in PBS-treated group, but no differences were observed in the levels of IL-4 and IL-5 (Supplementary Fig. 3). These results suggest that there could be some impact of β2 agonist treatment in dampening type 2 inflammation in RSV-infected neonates especially the production of IL-13 cytokine.Fig. 3β2-agonist treatment suppresses lung inflammation and mucus production in RSV-infected neonates.A The mRNA levels of Il6, Cxcl1, and Il1b were quantified from whole lung homogenates of RSV-infected neonates (7 dpi) after albuterol (Alb.) or PBS treatment at 2 and 5 dpi. Ordinary One-way ANOVA with uncorrected Fisher’s LSD test was used. For Il6, n = 9 (mock), n = 12 (RSV-PBS), and n = 14 (RSV-albuterol); and for Cxcl1 and Il1b, n = 8 (mock) and n = 12 (RSV) mice were used, data from 2 experiments. B Quantification of protein levels of cytokines and chemokines in the lungs from PBS- and albuterol-treated neonates at 7dpi was determined by LEGENDPlex assay. The two-tailed Mann-Whitney test was used. n = 10 mice per group was used except for IL-12p70 where n = 9 (PBS) and n = 7 (albuterol) mice were used, data from 2 experiments. C Production of TNF-α, CXCL-1, and IL-10 by BMDM cultures from wild-type (WT) mice at 8 h of stimulation with R848 in the presence and absence of albuterol (Alb., β2-agonist) or xamoterol (Xam., β1-agonist). Control = unstimulated controls. D Cytokine levels by BMDMs from WT Adrb2+/+ and Adrb2–/– mice at 8 h of stimulation with R848. Data from WT BMDMs in C are used for WT Adrb2+/+ in D for comparison. Data are from n = 4 biological replicates/group from 1 experiment (C, D). Ordinary one-way ANOVA with Sidak’s multiple comparisons post-test was used (C, D). E Representative 20X magnification images of PAS-stained lung sections from mock- and RSV-inoculated neonates at day 7 post-inoculation with and without albuterol treatment. Black arrows indicate PAS-positive mucus-producing cells in the airway epithelium. Mock-inoculated, n = 3 mice/group and RSV-infected, n = 4 mice/group were used, data from 1 experiment. Scale bar, 200 μm. F The mRNA levels of Gob5 and Muc5ac were quantified from lung homogenates of mock-and RSV-inoculated neonates at day 7 post-inoculation. Kruskal-Wallis test with uncorrected Dunn’s multiple comparisons was used. Mock group (n = 8 mice/group) except for Muc5ac albuterol group for which n = 6 mice were used. n = 12 mice (RSV-PBS) and n = 14 mice (RSV-Albuterol) and data in F are from 2 experiments. Data in (A)–(D), and (F) are shown in mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns = not significant. Exact p-values are included in the source data file. β2-agonist treatment suppresses lung inflammation and mucus production in RSV-infected neonates. A The mRNA levels of Il6, Cxcl1, and Il1b were quantified from whole lung homogenates of RSV-infected neonates (7 dpi) after albuterol (Alb.) or PBS treatment at 2 and 5 dpi. Ordinary One-way ANOVA with uncorrected Fisher’s LSD test was used. For Il6, n = 9 (mock), n = 12 (RSV-PBS), and n = 14 (RSV-albuterol); and for Cxcl1 and Il1b, n = 8 (mock) and n = 12 (RSV) mice were used, data from 2 experiments. B Quantification of protein levels of cytokines and chemokines in the lungs from PBS- and albuterol-treated neonates at 7dpi was determined by LEGENDPlex assay. The two-tailed Mann-Whitney test was used. n = 10 mice per group was used except for IL-12p70 where n = 9 (PBS) and n = 7 (albuterol) mice were used, data from 2 experiments. C Production of TNF-α, CXCL-1, and IL-10 by BMDM cultures from wild-type (WT) mice at 8 h of stimulation with R848 in the presence and absence of albuterol (Alb., β2-agonist) or xamoterol (Xam., β1-agonist). Control = unstimulated controls. D Cytokine levels by BMDMs from WT Adrb2+/+ and Adrb2–/– mice at 8 h of stimulation with R848. Data from WT BMDMs in C are used for WT Adrb2+/+ in D for comparison. Data are from n = 4 biological replicates/group from 1 experiment (C, D). Ordinary one-way ANOVA with Sidak’s multiple comparisons post-test was used (C, D). E Representative 20X magnification images of PAS-stained lung sections from mock- and RSV-inoculated neonates at day 7 post-inoculation with and without albuterol treatment. Black arrows indicate PAS-positive mucus-producing cells in the airway epithelium. Mock-inoculated, n = 3 mice/group and RSV-infected, n = 4 mice/group were used, data from 1 experiment. Scale bar, 200 μm. F The mRNA levels of Gob5 and Muc5ac were quantified from lung homogenates of mock-and RSV-inoculated neonates at day 7 post-inoculation. Kruskal-Wallis test with uncorrected Dunn’s multiple comparisons was used. Mock group (n = 8 mice/group) except for Muc5ac albuterol group for which n = 6 mice were used. n = 12 mice (RSV-PBS) and n = 14 mice (RSV-Albuterol) and data in F are from 2 experiments. Data in (A)–(D), and (F) are shown in mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns = not significant. Exact p-values are included in the source data file. Of note, RNAseq data from the Tabula Muris consortium34 and ImmGen database (www.immgen.org) show that lung macrophages and monocytes show high expression of both β1-AR (Adrb1) and β2-AR (Adrb2). We found that Adrb1 and Adrb2 are both present in lung homogenates from neonatal mice, and that albuterol treatment does not impact the expression level of either β-AR in the presence and absence of RSV infection (Supplementary Fig. 4). Next, we aimed to determine if β-AR signaling can promote modulation of cytokine production in macrophages exposed to a virus-like trigger. R848 (Resiquimod) is a synthetic ligand for TLR7/8 receptors, which also play key roles in recognizing RSV-derived RNA7,9. We used R848 to stimulate bone marrow-derived macrophages (BMDMs) in the presence of PBS, albuterol or xamoterol (a β1-agonist). We observed a significant decrease in the levels of pro-inflammatory cytokine (TNF-α) and chemokine (CXCL-1) by R848-treated BMDMs co-treated with albuterol (1 µM), but not by BMDMs co-treated with xamoterol (1 µM) (Fig. 3C), suggesting that β2-AR but not β1-AR signaling can significantly suppress proinflammatory cytokine production in macrophages. We found similar suppression of cytokine production by β2-agonist treatment of BMDMs that were derived from P14 neonates (Supplementary Fig. 5). Furthermore, levels of anti-inflammatory cytokine (IL-10) were robustly increased in R848-treated adult and neonatal BMDM cultures co-treated with β2-agonist, but not with β1-agonist (xamoterol) (Fig. 3C and Supplementary Fig. 5). Importantly, the immunosuppressive effects of albuterol were abolished when BMDMs were derived from Adrb2−⁄− mice (Fig. 3D). Interestingly, TNF-α and CXCL-1 levels were enhanced in Adrb2−⁄− BMDMs compared to wild-type BMDMs (Fig. 3D), indicating lack of ADRB2 leads to enhanced pro-inflammatory responses in macrophages. Together, our data indicate that β2−adrenergic signaling promotes anti-inflammatory responses in macrophages, and this may contribute to immunomodulation during RSV infection. One of the major characteristic features of severe RSV infection in children is RSV-induced goblet cell hyperplasia and mucus hypersecretion that can cause airway obstruction and respiratory failure35,36. However, the underlying mechanism of RSV-induced mucus secretion is not fully understood. Previous studies have demonstrated that TLR3, NF-κB, and p38/JNK-AP-1 signaling pathways induce mucins including MUC1 and MUC5AC35,37–39. Moreover, proinflammatory cytokines (such as IL-1 and TNF-α) promote NF-κB and the MAPK signaling to drive mucus overproduction38–40. To determine whether the host protective role of β2-AR signaling involves suppression of mucus production, we analyzed mucus production in infected lungs of neonates with and without β2-agonist treatment by performing Periodic acid-Schiff (PAS) staining. We found that numbers of mucus-producing goblet cells (dark pink cells) were markedly increased in lungs after 7dpi with RSV as compared to mock-inoculated mice (Fig. 3E). Albuterol treatment at 2 and 5 dpi robustly decreased this goblet cell hyperplasia and mucus production (Fig. 3E). In mock-inoculated neonates, albuterol treatment did not alter the goblet cell numbers in the lungs (Fig. 3E), suggesting decrease in goblet cell numbers in RSV-infected neonates with albuterol treatment is not due to off-target effects on mucus producing cells. To confirm further the PAS staining results, we assessed mRNA levels of Muc5ac and Gob5 genes. MUC5AC is a major mucin in the outer gel layer in respiratory mucus35. GOB5, a calcium-activated chloride channel expressed in secretary granules of goblet cells, has been positively associated with RSV-induced mucus secretion and disease severity41,42. We observed ∼ 2.3-fold increase in both Muc5ac and Gob5 mRNA levels in PBS-treated lung homogenates of RSV-infected neonates when compared to the levels in mock-inoculated neonates (Fig. 3F). In RSV-infected neonates with albuterol treatment, we observed a significant reduction of Muc5ac and Gob5 mRNA levels (Fig. 3F). Early life RSV infection and RSV-induced bronchiolitis can cause asthma-like symptoms at a later age. To determine the impact of neonatal β2-AR agonist treatment in development of asthma-like symptoms in later life, we performed Flexivent measurements of lung mechanics to assess pulmonary hyperresponsiveness in RSV-infected neonates at 12-15 weeks of age. As in other studies43–46, we used methacholine (6.25 mg/mL) as a positive control to assess the airway hyperreactivity (Resistance, Rrs; Elastance, Ers; Newtonian resistance, Rn; and tissue damping, G). As in previous studies with lung injury/infection43,47, all four measured airway hyperreactivity parameters were increased with methacholine (6.25 mg/mL) treatment as compared to without treatment (0 mg/mL) condition for both mock-inoculated and RSV-infected mice (Supplementary Fig. 6). However, the differences were found more significant among infected mice (Supplementary Fig. 6B). We did not find any difference in airway hyperreactivity between PBS- and albuterol-treated mice that were RSV-infected when they were 7 days old (Supplementary Fig. 6B), suggesting that albuterol treatment in RSV-infected neonates has no impact in development of RSV-induced pulmonary hyperresponsiveness during adulthood (12-15 weeks old). All together, these findings suggest that stimulating β2-AR signaling via agonist treatment dampens pathological lung inflammation and mucus secretion during RSV infection in neonates but has no impact on pulmonary hyperresponsiveness when infected neonates reach adulthood. β2-agonist treatment limits endothelial barrier disruption during neonatal RSV infection Another aspect of β2-adrenergic-mediated anti-RSV response could be via protection of vascular integrity. β2-AR gene (Adrb2) is expressed at high levels by lung ECs as seen in violin plots of single-cell RNAseq (scRNAseq) analyses from the Tabula Muris Consortium34, suggesting that agonist may signal to these cells (Fig. 4A). Lung histology data also showed that albuterol treatment decreased airway collapse and vascular leakiness of RBCs (Fig. 2). We hypothesized that β2-AR signaling may protect neonatal lungs from endothelial barrier disruption during RSV infection. To examine this, we employed various methods to determine the impact of β2-agonist treatment in endothelial barrier protection. We quantified the presence of protein, albumin, and RBCs in bronchoalveolar lavage (BAL) fluid at 7 dpi in RSV-infected neonates (Fig. 4B). Albuterol treatment decreased levels of total BAL protein compared to the levels in PBS-treated RSV-infected neonates (Fig. 4C). At baseline, we did not observe differences in total BAL protein levels between albuterol-and PBS-treated neonates (Supplementary Fig. 7A), suggesting β2-agonist treatment does not impact the airway barrier function at homeostasis. We also observed marked reduction in BAL albumin levels and the number of total RBCs (CD45-Ter119+ cells) in the BAL fluid (BALF) from albuterol-treated mice than that in PBS-treated mice at 7dpi (Fig. 4D, E, Supplementary Fig. 7B).Fig. 4Local β2-agonist treatment in RSV-infected neonates protects from endothelial barrier disruption.A Volcano plot of RNAseq data from Tabula Muris Consortium showing Adrb2 expression in different mouse lung cell types. Adrb2 expression by indicated cell types is shown in the x-axis. B Schematic showing intranasal RSV infection and local β2-agonist treatment at 2 and 5 dpi. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/lvlue9m. C The levels of total protein in BALF from RSV-infected neonates at 7 dpi after albuterol (Alb., β2-agonist) or PBS treatment. D (Left) Representative FACS plots showing RBCs (Ter119+CD45– cells) and leukocytes (CD45+ Ter119– cells) in BALF. Fluorescence minus one (FMO) plot show the negative staining control for Ter119. (Right) Quantitative comparison of total RBCs measured by flow cytometry analysis. E The levels of albumin in BALF from RSV-infected neonates with and without treatment with albuterol. n = 13 mice (PBS) for (C)–(E) and n = 15 mice (albuterol) for (C) and (E), and n = 11 mice (albuterol) for (D) were used, data from 2 to 3 experiments. One-tailed unpaired t-test was used and data are shown in mean ± SEM (C–E). *P < 0.05. F Heatmap of lung barrier associated gene expression in lung tissues after RSV infection. Lung mRNA levels of adhesion and tight junction proteins were quantified in mock- or RSV-inoculated neonates after treatment with albuterol or PBS. In the heatmap, mean fold changes for each group are shown. n = 7 (mock-PBS), n = 6 (mock-albuterol), n = 5 (RSV-PBS) and n = 7 (RSV-albuterol) mice were used, data from 1 experiment. G Representative confocal images of lung sections after immunofluorescence staining of P14 lung section. TH in green, sympathetic nerve fiber marker; CD31 in red, lung endothelial cell marker; and DAPI in blue, nuclei marker. The image on the left is 20X magnification, followed by a 63X optical magnification image in the middle from the selected area (in a rectangle) of the left image with Z-stack, and 63X magnification of the selected area (in a rectangle) of the middle image. The left 20X image and middle 63X image are 2×2 tiles. Scale bars, 100μm (left), 20μm (middle), and 10μm (right), data from 1 experiment (total 9 images of n = 3 mice). Exact p-values are included in the source data file. Local β2-agonist treatment in RSV-infected neonates protects from endothelial barrier disruption. A Volcano plot of RNAseq data from Tabula Muris Consortium showing Adrb2 expression in different mouse lung cell types. Adrb2 expression by indicated cell types is shown in the x-axis. B Schematic showing intranasal RSV infection and local β2-agonist treatment at 2 and 5 dpi. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/lvlue9m. C The levels of total protein in BALF from RSV-infected neonates at 7 dpi after albuterol (Alb., β2-agonist) or PBS treatment. D (Left) Representative FACS plots showing RBCs (Ter119+CD45– cells) and leukocytes (CD45+ Ter119– cells) in BALF. Fluorescence minus one (FMO) plot show the negative staining control for Ter119. (Right) Quantitative comparison of total RBCs measured by flow cytometry analysis. E The levels of albumin in BALF from RSV-infected neonates with and without treatment with albuterol. n = 13 mice (PBS) for (C)–(E) and n = 15 mice (albuterol) for (C) and (E), and n = 11 mice (albuterol) for (D) were used, data from 2 to 3 experiments. One-tailed unpaired t-test was used and data are shown in mean ± SEM (C–E). *P < 0.05. F Heatmap of lung barrier associated gene expression in lung tissues after RSV infection. Lung mRNA levels of adhesion and tight junction proteins were quantified in mock- or RSV-inoculated neonates after treatment with albuterol or PBS. In the heatmap, mean fold changes for each group are shown. n = 7 (mock-PBS), n = 6 (mock-albuterol), n = 5 (RSV-PBS) and n = 7 (RSV-albuterol) mice were used, data from 1 experiment. G Representative confocal images of lung sections after immunofluorescence staining of P14 lung section. TH in green, sympathetic nerve fiber marker; CD31 in red, lung endothelial cell marker; and DAPI in blue, nuclei marker. The image on the left is 20X magnification, followed by a 63X optical magnification image in the middle from the selected area (in a rectangle) of the left image with Z-stack, and 63X magnification of the selected area (in a rectangle) of the middle image. The left 20X image and middle 63X image are 2×2 tiles. Scale bars, 100μm (left), 20μm (middle), and 10μm (right), data from 1 experiment (total 9 images of n = 3 mice). Exact p-values are included in the source data file. Previous study has shown decreased expression of tight junction proteins in the lungs of RSV-infected mice48. Thus, we hypothesized that albuterol may help maintain barrier function and tight junction protein expression during RSV infection. We performed gene expression analyses of tight junction proteins and adhesion molecules in RSV-infected lungs with and without albuterol treatment. The mRNA expression levels of tight junction proteins including Claudin-1, Claudin-4 and Claudin-18 and Occludin, and adhesion molecule (E-Cadherin) were decreased in RSV-infected neonates compared to mock-inoculated mice and in albuterol treatment increased these levels (Fig. 4F). We also observed an effect of albuterol treatment in baseline induction of tight junction and adhesion molecules in mock-inoculated neonates (Fig. 4F). Moreover, albuterol treatment robustly increased the mRNA expression of cell proliferation marker Ki-67 in RSV-infected lungs when compared to the expression in PBS-treated infected mice, supporting the idea of increased cellular regeneration and barrier repair with β2-agonist treatment (Fig. 4F). We next sought to examine if sympathetic neurons are in close vicinity with lung endothelium to allow direct signaling to lung ECs. To determine this possibility, we performed immunohistochemistry of the lung sections from P14 neonates to examine co-localization of neurons and lung ECs. We stained the lung sections with EC marker (CD31) together with sympathetic neuronal marker (Tyrosine hydroxylase, TH). We observed sympathetic neurons (TH+ neurons), and ECs (CD31+) are situated in proximity in the airways as well as in lung parenchyma (Fig. 4G and Supplementary video 1-3). These results suggest that the lung endothelium and sympathetic neurons co-develop from an early stage of life and that there could be neuroendothelial signaling at play in our model. In sum, our data suggest that β2-AR stimulation via albuterol treatment increases the lung endothelial barrier function during RSV infection. Loss of β2-adrenergic signaling increases RSV-induced morbidity and lung pathology in neonates Since we observed decreased RSV-induced morbidity and immunopathology with β2-AR stimulation, we next determined whether β2-AR deficient mice may have worsened morbidity and lung pathology during RSV infection. To determine these, we infected P7 neonatal β2-AR-sufficient (Adrb2+/+) and β2-AR-deficient (Adrb2-/-) mice with RSV, followed by analysis of disease morbidity (Fig. 5A) and lung damage. As we demonstrated in Fig. 1, the percentage of body weight gain was markedly higher in mock-inoculated neonates as compared to the RSV-infected groups (Fig. 5B, C). We observed a marked decrease in percentage weight gain in RSV-infected Adrb2−/− neonates at 10-12 dpi when compared to percentage weight gain in RSV-infected Adrb2+/+ neonates, suggesting loss of β2-AR shows a negative impact in controlling RSV infection and disease severity (Fig. 5C). The decrease in body weight among Adrb2−/− neonates was observed to be >6.5% on average when compared to Adrb2+/+ neonates during 6-13 dpi and >9.5% on average during 10-12 dpi (Fig. 5C). Consistent with weight gain data among mock-inoculated neonates, we did not observe difference in body weight in Adrb2−/− vs. Adrb2+/+ neonates up to 4-6 dpi in RSV-inoculated groups (Fig. 5C), suggesting the effect of β2-adrenergic signaling blockade in the morbidity of RSV-infected neonates does not develop rapidly following RSV infection. Furthermore, we did not find a significant difference in actual body weight (g) due to β2-AR deficiency at day 0 of inoculation for the P7 neonates in Fig. 5B, C except a modest increase in weight of the RSV-infected Adrb2–/– neonates when compared to the weight of RSV-infected Adrb2+/+ neonates (Supplementary Fig. 8). These RSV-infected P7 Adrb2–/– neonates also showed increased body weight when compared to mock-inoculated P7 Adrb2–/– and Adrb2+/+ neonates, suggesting a developmental and maternal nursing effect for the increased body weight for this neonatal group at day 0 of inoculation.Fig. 5Blockade of β2−adrenergic signaling suppresses neonatal host defense to RSV infection.A Schematic showing Adrb2+/+ and Adrb2–/– P7 neonates were intranasally (i.n.) inoculated with mock or RSV (1.6 ×106 TCID50/10 μL per neonate), followed by daily body weight measurements until days 14 of post-inoculation. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/b4b677m. B Weight change difference between Adrb2+/+ and Adrb2−⁄− mice after mock inoculation in percentage original weight scale on the Y-axis for 14-day post-inoculation period (till P21). C Weight change difference between Adrb2+/+ and Adrb2−⁄− mice after RSV infection for 14 dpi (till P21). Two-way repeated measure ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used (B, C). n = 6 (mock-Adrb2+/+), n = 8 (mock-Adrb2−⁄−), and n = 12 (RSV, Adrb2+/+and Adrb2−⁄−) mice (males and females) were used, pooled from 2 experiments. Data in B and C are shown in mean ± SEM. *P < 0.05. ns, not significant. Exact p-values are included in the source data file. Blockade of β2−adrenergic signaling suppresses neonatal host defense to RSV infection. A Schematic showing Adrb2+/+ and Adrb2–/– P7 neonates were intranasally (i.n.) inoculated with mock or RSV (1.6 ×106 TCID50/10 μL per neonate), followed by daily body weight measurements until days 14 of post-inoculation. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/b4b677m. B Weight change difference between Adrb2+/+ and Adrb2−⁄− mice after mock inoculation in percentage original weight scale on the Y-axis for 14-day post-inoculation period (till P21). C Weight change difference between Adrb2+/+ and Adrb2−⁄− mice after RSV infection for 14 dpi (till P21). Two-way repeated measure ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used (B, C). n = 6 (mock-Adrb2+/+), n = 8 (mock-Adrb2−⁄−), and n = 12 (RSV, Adrb2+/+and Adrb2−⁄−) mice (males and females) were used, pooled from 2 experiments. Data in B and C are shown in mean ± SEM. *P < 0.05. ns, not significant. Exact p-values are included in the source data file. The increased morbidity of RSV-infected Adrb2−/− neonates was consistent with augmented lung damage and barrier disruption as observed by H&E analyses of lung sections of Adrb2−/− neonates at 7dpi (Fig. 6A, B). While there were no differences in baseline alveolar/perivascular structures and inflammation of the lungs between Adrb2−/− and Adrb2+/+ neonates with mock inoculation, Adrb2−/− neonates showed a marked increased airway cellular influx and damage compared to Adrb2+/+ neonates at 7 dpi with RSV (Fig. 6B, C). Of note, we also observed an increase in airway RBCs in Adrb2−/− mice at the baseline level, indicating the importance of β2AR in baseline barrier maintenance (Fig. 6C).Fig. 6Loss of β2-adrenergic receptor and sympathetic neurons augment lung pathology to neonatal RSV infection.A Representative 1X magnification of Hematoxylin and Eosin (H&E)-stained lung section images of Adrb2+/+ and Adrb2–/– neonates at day 7 post-inoculation after mock or RSV inoculation, data from 1 experiment. Scale bar, 3 mm. B Representative 20X magnification of 1X lung section images (area shown in rectangles) showing lung pathology and airway disruption in mock-and RSV-inoculated lungs. Scale bar, 200 µm. C Quantitative scoring of lung pathology. Sample size of Adrb2+/+ (mock) n = 4 mice, Adrb2–/– (mock) n = 3 mice, Adrb2+/+ (RSV) n = 5 mice and Adrb2–/– (RSV) n = 3 mice were used, data from 1 experiment. Ordinary Two-way ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. D Representative 1X magnification of H&E-stained lung section images of vehicle- and 6-OHDA-treated mock- and RSV-inoculated neonates at day 7 post-inoculation, data from 1-2 experiments with similar results. Scale bar, 3 mm. E Representative 20X magnification of 1X lung section images (area shown in rectangles) showing lung pathology and airway disruption in mock and RSV-inoculated lungs. Scale bar, 200 µm. F Quantitative scoring of lung pathology. Sample size of vehicle-treated (mock) n = 3 mice, 6-OHDA (6-Hydroxydopamine)-treated (mock) n = 4 mice, vehicle-treated (RSV) n = 7 mice, and 6-OHDA-treated (RSV) n = 7 mice were used, data from 1-2 experiments. Ordinary Two-way ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. Data in C and F are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact p-values are included in the source data file. Loss of β2-adrenergic receptor and sympathetic neurons augment lung pathology to neonatal RSV infection. A Representative 1X magnification of Hematoxylin and Eosin (H&E)-stained lung section images of Adrb2+/+ and Adrb2–/– neonates at day 7 post-inoculation after mock or RSV inoculation, data from 1 experiment. Scale bar, 3 mm. B Representative 20X magnification of 1X lung section images (area shown in rectangles) showing lung pathology and airway disruption in mock-and RSV-inoculated lungs. Scale bar, 200 µm. C Quantitative scoring of lung pathology. Sample size of Adrb2+/+ (mock) n = 4 mice, Adrb2–/– (mock) n = 3 mice, Adrb2+/+ (RSV) n = 5 mice and Adrb2–/– (RSV) n = 3 mice were used, data from 1 experiment. Ordinary Two-way ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. D Representative 1X magnification of H&E-stained lung section images of vehicle- and 6-OHDA-treated mock- and RSV-inoculated neonates at day 7 post-inoculation, data from 1-2 experiments with similar results. Scale bar, 3 mm. E Representative 20X magnification of 1X lung section images (area shown in rectangles) showing lung pathology and airway disruption in mock and RSV-inoculated lungs. Scale bar, 200 µm. F Quantitative scoring of lung pathology. Sample size of vehicle-treated (mock) n = 3 mice, 6-OHDA (6-Hydroxydopamine)-treated (mock) n = 4 mice, vehicle-treated (RSV) n = 7 mice, and 6-OHDA-treated (RSV) n = 7 mice were used, data from 1-2 experiments. Ordinary Two-way ANOVA with uncorrected Fisher’s LSD test for multiple comparisons was used. Data in C and F are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact p-values are included in the source data file. Sympathetic neurons represent the major cell type that drive β2-AR stimulation via releasing NA in the lungs and have been found to modulate both LPS-induced and type 2 inflammation in the lung23,49. To determine their role in RSV infection, we depleted sympathetic neurons in P4 neonates via treatment with 6-Hydroxydopamine (6-OHDA), which leads to chemical sympathectomy. The 6-OHDA- vs. vehicle- treated mice were then intranasally infected with RSV at P12. Consistent with histopathology results in Adrb2−/− and Adrb2+/+ neonates, we observed increased airway inflammation and alveolar damage in 6-OHDA-treated neonates at 7 dpi as compared to the inflammation and damage in vehicle-treated neonates (Fig. 6D-F). Mock-inoculated 6-OHDA- vs. vehicle-treated mice did not show major baseline differences in lung inflammation or immune cell influx due to neuronal ablation (Fig. 6D-F). Collectively, these data suggest that the endogenous blockade of β2-AR signaling dampens the neonatal host defense to RSV by increasing morbidity and lung pathology in neonates. β2-adrenergic signaling increases monocyte recruitment and regulates the abundance of interstitial macrophages during RSV infection Like other respiratory viral infections, RSV infection leads to increase in leukocyte numbers in the lungs, mainly the numbers of neutrophils, monocytes, macrophages and lymphocytes50–52. Tissue-resident immune cells in the lung (such as alveolar macrophages, AMs) and airway epithelium engulf RSV viral particles or RSV-infected cellular debri, and secrete cytokines and chemokines that regulate the entry of myeloid and lymphoid cells into the lung, and enhance viral clearance52,53. Lung-infiltrating T cells play an indispensable role in killing of virus-infected cells and preventing viral replication in the lung9,53. To delineate the role of β2-adrenergic signaling on composition of immune cell infiltrates at the site of infection, we performed immune subset analysis of recruited and non-recruited cells in the airways in albuterol-treated versus PBS-treated neonates (Supplementary Fig. 9A). After RSV infection, albuterol-treated neonates showed similar numbers of total BAL cells as in PBS-treated neonates at 7 dpi (Fig. 7A), suggesting albuterol treatment does not have an impact on airway recruitment of total cells after RSV infection. Similar to previous findings28,52, we observed significant increase in total BAL and CD45+ cells in RSV-infected neonatal lungs as compared to the numbers in mock-inoculated neonates (Fig. 7A, B). At mock-inoculated groups of mice, we did not find difference in baseline total BAL cells and leukocytes (CD45+ cells) (Fig. 7A, B), suggesting no effect of albuterol treatment in baseline immune cell influx in airways. Immune subset analyses in BALF at 7dpi showed a reduction trend in total numbers of B cells (CD45+CD11b− B220+ cells) and CD4+ T cells and significant increase in total number of interstitial macrophages (IMs, CD45+CD11b+ Ly6G− F4/80+Siglec-F− cells) in albuterol-treated neonates as compared to the numbers in PBS-treated neonates (Supplementary Fig. 9B-C and Fig. 7C). Furthermore, we did not observe significant differences in absolute numbers of AMs, neutrophils, CD8+ T cells, NK cells and non-T/B/NK cells (Supplementary Fig. 9B-C) and the levels of IgA in the BALF (Supplementary Fig. 9D) between PBS-and albuterol-treated neonates, suggesting a minor or no role of adaptive immune cell numbers in β2-AR-mediated control of RSV infection.Fig. 7β2-adrenergic signaling increases monocyte recruitment and regulates the abundance of interstitial macrophages during RSV infection.Total BAL cell numbers (A), and representative FACS plots of leukocytes (CD45+ cells) (left) and quantification data of BAL leukocytes (right) (B), in mock-and RSV-inoculated neonates at day 7 post-inoculation with and without albuterol (Alb.) treatment. C Representative FACS plots of interstitial macrophages (IMs) (left) and quantification data of BAL IMs (right), in the BALF from mock-and RSV-inoculated neonates at day 7 post-inoculation after PBS or albuterol treatment. IMs were characterized as CD45+CD11b+Siglec-F−Ly6G−F4/80+ cells. n = 3 mice (mock), n = 19 mice (RSV-PBS), and n = 20 mice (RSV-albuterol) were used (A–C), data from 1-3 experiments. D Representative FACS plots of IMs (left), and quantification data of IMs (right), in the whole lungs from mock- and RSV-inoculated neonates at day 7 post-inoculation after PBS or albuterol treatment. E, F Percentages and cell numbers of, (E) myeloid subsets, and (F) lymphoid subsets, in RSV-infected neonatal lungs at 7 dpi after PBS or albuterol treatment. G Representative FACS plots of RSV-specific (Tetramer+) CD8+ T cells from RSV-infected neonates at 7dpi with PBS and albuterol treatment (left). The fluorescence minus one (FMO) plot is shown as a negative staining control of Tetramer+ CD8+ T cells. Percentage and absolute number of RSV-specific CD8+ T cells in the whole lungs from RSV-infected neonates at 7dpi with PBS and albuterol treatment (right). n = 3 (mock-PBS), n = 4 (mock-albuterol), and n = 8 (RSV-PBS), n = 9 mice (RSV-albuterol) were used (D–G), data from 1-3 experiments. Statistical analyses include Kruskal-Wallis test with uncorrected Dunn’s multiple comparisons post-tests (A–C), Brown Forsythe and Welch ANOVA (D), two-tailed Unpaired t-test (E–G). Data are shown as mean ± SEM. *P < 0.05, **P < 0.01. ns, not significant. Exact p-values are included in the source data file. β2-adrenergic signaling increases monocyte recruitment and regulates the abundance of interstitial macrophages during RSV infection. Total BAL cell numbers (A), and representative FACS plots of leukocytes (CD45+ cells) (left) and quantification data of BAL leukocytes (right) (B), in mock-and RSV-inoculated neonates at day 7 post-inoculation with and without albuterol (Alb.) treatment. C Representative FACS plots of interstitial macrophages (IMs) (left) and quantification data of BAL IMs (right), in the BALF from mock-and RSV-inoculated neonates at day 7 post-inoculation after PBS or albuterol treatment. IMs were characterized as CD45+CD11b+Siglec-F−Ly6G−F4/80+ cells. n = 3 mice (mock), n = 19 mice (RSV-PBS), and n = 20 mice (RSV-albuterol) were used (A–C), data from 1-3 experiments. D Representative FACS plots of IMs (left), and quantification data of IMs (right), in the whole lungs from mock- and RSV-inoculated neonates at day 7 post-inoculation after PBS or albuterol treatment. E, F Percentages and cell numbers of, (E) myeloid subsets, and (F) lymphoid subsets, in RSV-infected neonatal lungs at 7 dpi after PBS or albuterol treatment. G Representative FACS plots of RSV-specific (Tetramer+) CD8+ T cells from RSV-infected neonates at 7dpi with PBS and albuterol treatment (left). The fluorescence minus one (FMO) plot is shown as a negative staining control of Tetramer+ CD8+ T cells. Percentage and absolute number of RSV-specific CD8+ T cells in the whole lungs from RSV-infected neonates at 7dpi with PBS and albuterol treatment (right). n = 3 (mock-PBS), n = 4 (mock-albuterol), and n = 8 (RSV-PBS), n = 9 mice (RSV-albuterol) were used (D–G), data from 1-3 experiments. Statistical analyses include Kruskal-Wallis test with uncorrected Dunn’s multiple comparisons post-tests (A–C), Brown Forsythe and Welch ANOVA (D), two-tailed Unpaired t-test (E–G). Data are shown as mean ± SEM. *P < 0.05, **P < 0.01. ns, not significant. Exact p-values are included in the source data file. We also quantified myeloid and lymphoid subsets in whole lungs from RSV-infected neonates after albuterol or PBS treatment by flow cytometry (Supplementary Fig. 10A). Similar to results in BALF immunophenotyping, albuterol- vs. PBS-treated neonates did not show major differences in leukocyte numbers (Supplementary Fig. 10B), but showed an increased percentage and number of IMs (CD45+CD11b+ Ly6G− Siglec-F− F4/80+ cells) with albuterol treatment (Fig. 7D). Also, the numbers of Ly6chi monocytes (CD45+CD11b+Ly6G− F4/80− Ly6chi cells) and Ly6clo monocytes (CD45+CD11b+Ly6G− F4/80− Ly6clo cells) were increased with albuterol treatment as compared to the numbers in PBS-treated neonates (Fig. 7E). There were no differences in CD4+ T and B cell numbers in the lungs in both groups (Fig. 7F, Supplementary Fig. 11). At mock-inoculated groups of neonates at 7 days post-inoculation, we did not find difference in baseline numbers of total IMs in BALF and whole lungs (Fig. 7C, D), suggesting albuterol-mediated promotion of increase in IM numbers occur during RSV infection only. Consistent to BAL immune cell number data, we did not observe significant differences in the numbers of AMs, CD8+ T cells, NK cells and non-T/B/NK cells in RSV-infected lungs with and without albuterol treatment (Fig. 7E, F). Also, the total number of RSV-specific CD8+ T cells did not change in albuterol-and PBS-treated neonates at 7dpi (Fig. 7G, Supplementary Fig. 11), suggesting β2-adrenergic control of RSV infection does not involve the increased recruitment of RSV-specific CD8+ T cells. Altogether, our immunophenotyping results from BALF and lungs suggest a link of β2-adrenergic signaling pathway in recruitment and maintenance of IMs in anti-RSV host response. β2-adrenergic signaling pathway enhances viral clearance via interferon-λ production during neonatal RSV infection While myeloid cells (such as macrophages, DC, monocytes) were found to secrete type I IFNs (IFN-α, IFN-β) during RSV infection30,52, respiratory epithelial cells were demonstrated to produce IFN-λ during influenza virus infection and confers host protection in mice against influenza virus challenge54. Myeloid and epithelial cells mediate potent antiviral effects to viral infection via multiple mechanisms, involving suppression of viral mRNA synthesis, translation of viral particles and assembly of virus particles9. We thus asked whether β2-adrenergic-mediated protection against RSV infection involves enhanced RSV viral clearance and IFN production. To investigate this possibility, we quantified mRNA levels of both RSV and IFNs in the lung homogenates after RSV infection. To determine RSV multiplication, we quantified the RSV L (RNA-dependent RNA polymerase) and RSV N (nucleoprotein) viral copies per µg of mRNA by qPCR analyses of RSV-infected lungs. We also performed qPCR analyses to quantify the mRNA levels of IFNs (IFN-α, IFN-β, and IFN-λ) in the lung homogenates. First, we performed time-course analyses of viral load and IFN production at 2, 3, 4, 5, and 7 dpi. The viral copies of RSV N were detected starting from 2 dpi up to 7 dpi (Supplementary Fig. 12A). To quantify the live infectious viral titers and assess active RSV replication in infected lungs, we performed a plaque-forming assay as published in other studies55,56. Similar to qPCR viral load results, we detected infectious viral titers (as plaque-forming units, PFUs) from 2 to 7 dpi, with a maximal titer at 3 and 5 dpi (Supplementary Fig. 12B). We found significantly increased viral titers at 5 dpi compared to 2 dpi, an indication of active viral replication in infected neonates (Supplementary Fig. 12B). The production of IFN-β (Ifnb1 mRNA expression) peaked at 3 and 4 dpi, followed by at 7-dpi (Supplementary Fig. 12C). In contrast, production levels of IFN-λ (Ifnl2 mRNA expression) was found to peak at 5-7 dpi (Supplementary Fig. 12C). The early IFN-β production was paralleled with suppressed viral load, whereas IFN-λ production at latter phase of infection was found to be associated with suppressed viral load at 7 dpi (Supplementary Fig. 12A and 12C). To determine the full efficacy of two doses of β2-agonist treatment (at 2 and 5 dpi), we then analyzed the impact of albuterol treatment in viral load and IFN production at 7 dpi. While there were no detectable viral copies of RSV L and N genes in mock-inoculated lungs of albuterol-and PBS-treated neonates at 7 days post-inoculation, we observed robust suppression of viral copy numbers of RSV N and L genes in albuterol-treated neonates at 7dpi as compared to the levels in PBS-treated group (Fig. 8A). We also found a significant reduction in PFU numbers in the lung homogenates from albuterol-treated neonates when compared to the numbers in PBS-treated mice (Fig. 8B), suggestive of reduction of infectious viral titers in the lungs with local albuterol treatment. To complement our results regarding increased RSV clearance in β2-agonist-treated neonates, we also performed immunohistochemical staining of RSV (all antigens) in the lung tissue sections collected from PBS- and albuterol-treated neonates at 7 dpi. We found that the lung sections from albuterol-treated neonates showed a small fraction of the airway epithelium positive for RSV (Supplementary Fig. 13). In contrast, in PBS-treated neonates, RSV was distributed throughout the airway epithelium (Supplementary Fig. 13). Further, we found visibly more airway damage and epithelial sloughing (shown by white arrows) in PBS-treated RSV-infected neonates than the airway damage in albuterol-treated infected neonates (Supplementary Fig. 13).Fig. 8β2-adrenergic signaling enhances viral clearance via interferon λ production during neonatal RSV infection.A The absolute quantification of RSV L and RSV N in lung homogenates from mock- or RSV-inoculated neonates after albuterol (Alb.) treatment. Kruskal-Wallis statistics with Dunn’s multiple comparisons post-test was used. n = 5 mice/group (mock and RSV-PBS) and n = 7/group (RSV-albuterol) were used; data represent from 1 of 2 experiments. B Representative images of plaques (from 3 mice/group) from RSV-infected neonates (7 dpi) (left). The numbers of plaques counted (right). n = 9 (PBS) and n = 12 (albuterol) mice for RSV-infected groups, and n = 4 (mock) mice were used, data from 1-2 experiments. C mRNA expression levels of IFNs in the lung homogenates from mock- or RSV- inoculated neonates. For Ifna1, n = 8 (mock), n = 12 (RSV) mice; for Ifnb1, n = 11 (mock-PBS), n = 9 (mock-albuterol), n = 12 (RSV-PBS), and n = 14 (RSV-albuterol); and for Ifnl2, n = 7 (mock-PBS), n = 5 (mock-albuterol), n = 12 (RSV-PBS), and n = 13 (RSV-albuterol) mice were used, data from 2 experiments. Quantification of RSV L and RSV N (D), and IFN mRNA (E), in whole lungs of Adrb2+/+ and Adrb2–/– mice. n = 9 mice/group (D). For Ifna1, n = 10 (Adrb2+/+), n = 9 (Adrb2–/–); for Ifnb1, n = 9 (Adrb2+/+), n = 10 (Adrb2–/–); and for Ifnl2, n = 8 (Adrb2+/+), n = 9 (Adrb2–/–) mice were used (E). Data from 2 experiments (D, E). Quantification of viral copies (F), and IFN mRNA (G), in RSV-infected lungs of vehicle (Veh.)-and 6-OHDA-treated mice at 7 dpi. n = 6 (vehicle) and n = 7 (6-OHDA) mice (F). For Ifna1, n = 7 (vehicle), n = 9 (6-OHDA); for Ifnb1, n = 6 (vehicle), n = 9 (6-OHDA); and for Ifnl2, n = 7 (vehicle and 6-OHDA) mice were used (G). Data from 2 experiments (F, G). The relative IFN gene expression is shown in the heatmaps in C, E, and G. H Schematic showing RSV infection and IFN-λ2 treatment. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/qrpr289. I Quantification of viral load in PBS- and IFN-λ2-treated neonates. n = 8 (PBS), and n = 10 (IFN-λ2) mice per group, data from 1 to 2 experiments. The two-tailed Unpaired t-test & Mann-Whitney test were used (B, D, F, I). Data in A, B, D, F, and I are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Exact p-values are included in the source data file. β2-adrenergic signaling enhances viral clearance via interferon λ production during neonatal RSV infection. A The absolute quantification of RSV L and RSV N in lung homogenates from mock- or RSV-inoculated neonates after albuterol (Alb.) treatment. Kruskal-Wallis statistics with Dunn’s multiple comparisons post-test was used. n = 5 mice/group (mock and RSV-PBS) and n = 7/group (RSV-albuterol) were used; data represent from 1 of 2 experiments. B Representative images of plaques (from 3 mice/group) from RSV-infected neonates (7 dpi) (left). The numbers of plaques counted (right). n = 9 (PBS) and n = 12 (albuterol) mice for RSV-infected groups, and n = 4 (mock) mice were used, data from 1-2 experiments. C mRNA expression levels of IFNs in the lung homogenates from mock- or RSV- inoculated neonates. For Ifna1, n = 8 (mock), n = 12 (RSV) mice; for Ifnb1, n = 11 (mock-PBS), n = 9 (mock-albuterol), n = 12 (RSV-PBS), and n = 14 (RSV-albuterol); and for Ifnl2, n = 7 (mock-PBS), n = 5 (mock-albuterol), n = 12 (RSV-PBS), and n = 13 (RSV-albuterol) mice were used, data from 2 experiments. Quantification of RSV L and RSV N (D), and IFN mRNA (E), in whole lungs of Adrb2+/+ and Adrb2–/– mice. n = 9 mice/group (D). For Ifna1, n = 10 (Adrb2+/+), n = 9 (Adrb2–/–); for Ifnb1, n = 9 (Adrb2+/+), n = 10 (Adrb2–/–); and for Ifnl2, n = 8 (Adrb2+/+), n = 9 (Adrb2–/–) mice were used (E). Data from 2 experiments (D, E). Quantification of viral copies (F), and IFN mRNA (G), in RSV-infected lungs of vehicle (Veh.)-and 6-OHDA-treated mice at 7 dpi. n = 6 (vehicle) and n = 7 (6-OHDA) mice (F). For Ifna1, n = 7 (vehicle), n = 9 (6-OHDA); for Ifnb1, n = 6 (vehicle), n = 9 (6-OHDA); and for Ifnl2, n = 7 (vehicle and 6-OHDA) mice were used (G). Data from 2 experiments (F, G). The relative IFN gene expression is shown in the heatmaps in C, E, and G. H Schematic showing RSV infection and IFN-λ2 treatment. Created in BioRender. Adhikari, S. (2025) https://BioRender.com/qrpr289. I Quantification of viral load in PBS- and IFN-λ2-treated neonates. n = 8 (PBS), and n = 10 (IFN-λ2) mice per group, data from 1 to 2 experiments. The two-tailed Unpaired t-test & Mann-Whitney test were used (B, D, F, I). Data in A, B, D, F, and I are shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Exact p-values are included in the source data file. Moreover, we observed an increased mRNA levels of IFN-λ (∼1.9 fold) in the lung homogenates between mock-and RSV-inoculated neonates at day 7 post-inoculation, confirming that the RSV infection increases IFN-λ production (Fig. 8C). With albuterol treatment at 2 and 5 dpi, we found a higher levels of IFN-λ mRNA in RSV-infected neonates at 7dpi (Fig. 8C). When quantified in protein levels, we observed an increase in IFN-λ protein in the lung homogenates from albuterol-treated neonates when compared to IFN-λ levels in PBS-treated neonates at 7dpi (Supplementary Fig. 14). We did not observe significant changes in expression levels of Ifna1 and Ifnb1 between albuterol-and PBS-treated mice at 7dpi, indicating β2-agonist treatment has a minor impact in production of type I IFNs during RSV infection (Fig. 8C). Also, we did not observe increase in expression levels of interferon-stimulated genes (ISGs) with albuterol treatment (Supplementary Fig. 15), implying a minor role of ISG upregulation in neighboring cells for antiviral responses in β2-agonist-treated neonates. To further confirm the antiviral role of β2-adrenergic signaling in RSV infection, we pursued to investigate the viral load and IFN production in Adrb2+/+ and Adrb2−/− neonates at 7dpi. Consistent with the results with β2-AR agonism, we found an increase of viral copies of RSV N and L genes in the lungs of Adrb2−/− neonates as compared to the levels in Adrb2+/+ neonates (Fig. 8D). These results are well correlated with marked decrease in Ifnl2 expression levels in Adrb2−/− neonates (Fig. 8E). Decrease in RSV clearance and IFN-λ production in Adrb2−/− neonates was also observed in sympathetic neuron-ablated [6-Hydroxydopamine (6-OHDA)-treated] neonates when compared to vehicle-treated neonates (Fig. 8F, G). Finally, we confirmed the antiviral effect of IFN-λ in neonatal RSV infection by intranasal administration of two doses of recombinant IFN-λ2 in RSV-infected neonates and analyzing the RSV load in the lungs at 7 dpi (Fig. 8H, I). We found significant suppression of viral replication as judged by viral copy numbers of RSV L and N genes in IFN-λ2-treated neonates when compared with viral replication in vehicle-treated neonates (Fig. 8I). It is possible that β2-agonist treatment enhances the phagocytosis of viral particles and RSV-infected cells for viral clearance. To determine the extent to which β2-agonist impacts the phagocytic capacity of monocytes and macrophages during RSV infection, we assessed the impact of albuterol treatment on RSV binding/phagocytosis in neonatal BMDMs by examining the expression levels of phagocytosis receptors and the extent of RSV surface binding and phagocytosis in BMDMs. We first challenged neonatal BMDMs with different doses of live RSV to validate macrophages responding to live RSV infection. As expected, we found a dose-dependent increase in the expression of IL-6 mRNA with a multiplicity of infection (MOI) of 1 to 10 (Supplementary Fig. 16A). The increase in cytokine response is consistent with increased RSV binding and phagocytosis, as judged by a dose-dependent increase in RSV viral load in macrophages that were washed with PBS before analyzing the viral load (Supplementary Fig. 16B). In albuterol-treated BMDMs, we found robust suppression of Tnfa mRNA levels (Supplementary Fig. 16C), consistent with our in vitro cytokine data showing albuterol suppresses TNF-α production when stimulated with R848 (Supplementary Fig. 5). These albuterol-treated RSV-infected BMDMs (MOI of 5) also exhibited increased viral load, as indicated by increased RSV N gene copy numbers from BMDM lysates (Supplementary Fig. 16B). Furthermore, mRNA level analyses of phagocytosis markers showed increased expression of Mrc1 (code for CD206), Tlr4, and Cd14 in RSV-infected macrophages treated with albuterol as compared to the expression levels in PBS-treated RSV-infected macrophages (Supplementary Fig. 16D). Interestingly, albuterol robustly increased the baseline expression of Cd14 and Tlr4, but not the baseline expression of Mrc1 and Fcgr1 (Supplementary Fig. 16D). These results suggest that albuterol treatment enhances the expression of phagocytosis receptors, contributing to the enhanced phagocytosis of RSV viral particles and/or RSV-infected cell debris. In summary, we demonstrate a critical role of β2AR signaling axis in controlling RSV replication in neonates via promoting type III IFN production and phagocytosis. Discussion The role of nervous system in antiviral immunity in early life infection is still not well understood. Our study produces insight into the role of adrenergic signaling in promoting antiviral defense mechanisms in neonatal mice, by a complex interaction with lung immune, endothelial and epithelial cells during respiratory infections. We employed multiple genetic and pharmacological approaches to show that the β2-AR signaling axis plays a key role in the host response to RSV. Given that β2-agonists (albuterol, salmeterol) are currently being used to treat asthma and COPD, our work also reveals a potential therapeutic role for these drugs in improving disease morbidity and viral clearance during RSV infections. Primary RSV infection or vaccine does not provide long-term immunity in infants/children and reinfection can still cause severe RSV disease. Therefore, it is crucial to understand the endogenous mechanism of control of RSV infection for the effective treatment strategy. Our study demonstrates a mouse model where RSV lung infection in C57BL/6 J neonates cause disease morbidity, inflammation, mucus production and barrier breakdown (Fig. 9A). Our results support the concept that sympathetic neurons and β2-AR signaling protect neonates from viral expansion and airway barrier breakdown, thereby promoting antiviral defense against RSV. Further, we showed that the sympathetic neuron ablation and β2-AR deficiency increases the RSV viral load and immunopathology in neonates. In contrast, β2-AR agonism (via β2-agonist treatment) robustly increases viral clearance, anti-inflammatory response, and barrier protection in RSV-infected neonates (Fig. 9B). These events are paralleled with increased mucus clearance in the airways to prevent airway blockade and respiratory failure (Fig. 9B).Fig. 9Model showing the control of neonatal RSV infection by β2-adrenergic signaling.Stimulating β2-adrenergic signaling pathway by intranasal administration of β2-agonist controls RSV infection in neonates. RSV infection in neonate leads to viral expansion, inflammation, mucus overproduction, barrier breakdown and reduced IFN-λ production (A). A β2-agonist treatment in RSV-infected neonate suppresses lung damage, endothelial barrier disruption, mucus overproduction, and viral replication, which cumulatively promote the host defense (B). Created in BioRender. Adhikari, S. (2025) https://BioRender.com/m19f314. Model showing the control of neonatal RSV infection by β2-adrenergic signaling. Stimulating β2-adrenergic signaling pathway by intranasal administration of β2-agonist controls RSV infection in neonates. RSV infection in neonate leads to viral expansion, inflammation, mucus overproduction, barrier breakdown and reduced IFN-λ production (A). A β2-agonist treatment in RSV-infected neonate suppresses lung damage, endothelial barrier disruption, mucus overproduction, and viral replication, which cumulatively promote the host defense (B). Created in BioRender. Adhikari, S. (2025) https://BioRender.com/m19f314. Previous murine studies have observed the context-dependent role of neurons in antimicrobial immunity to pathogens in adult mice. We have identified the host detrimental role of nociceptor sensory neurons during bacterial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) by suppressing neutrophil recruitment and surveillance, and γδ T cell responses57. This host detrimental role involves the increased calcitonin gene-related peptide (CGRP)-CGRP receptor signaling after MRSA infection57. In contrast, nociceptors and CGRP signaling were found to mediate host defense against Salmonella Typhimurium enteric invasion by suppressing levels of M cells in the ileum58 and against Candida albicans skin infections by enhancing Th17 immunity59,60. Nociceptor sensory neurons also control the magnitude of CD8+ T cell priming and expansion during HSV-1 skin infection in mice61. Our results of enhanced host protection to RSV with sympathetic neural signaling intact and β2-AR simulation are consistent with previous studies. However, in contrast to previous findings, these host protective responses involve enhanced type III IFN production and viral clearance and are independent of T and B cell recruitment. While type I IFNs (IFN-α, IFN-β) mediate viral restriction and antiviral defense to RSV, the role of IFN-λ in viral clearance during RSV infection is less understood. During RSV infection in adult C57BL/6 J mice, type I IFNs were demonstrated to be produced by AMs via mitochondrial antiviral signaling protein (MAVS)–coupled retinoic acid–inducible gene 1 (RIG-I)–like receptors, and loss of MAVS was shown to impair the lung RSV clearance52. The levels of IFN-β are not different in albuterol- vs. PBS-treated RSV-infected neonates. However, its level slightly reduced in neuron-ablated neonates as compared to the levels in non-ablated neonates at 7dpi (Fig. 8G), suggesting sympathetic neural signals might regulate the expression of IFN-β during neonatal RSV infection. Intriguingly, we observed robust increased levels of Ifnl2 mRNA in the whole lung lysates from RSV-infected neonates from albuterol-treated neonates and decreased levels of Ifnl2 mRNA in Adrb2−/− and sympathetic neuron-ablated neonates (Fig. 8C, E, G), suggesting β2-AR signaling is crucial for IFN-λ production and that loss of β2-AR signaling impacts the production level of IFN-λ in RSV-infected neonates. Our findings suggest a role of β2-adrenergic signaling in regulating IM and monocyte numbers during neonatal RSV infection. Previous study found that the type I IFN-producing AMs drive recruitment of CD64hi inflammatory cells (IMs, monocytes, MoDC) for viral clearance and host protection against RSV infection in adult mice52. Based on our BAL and whole lung immune analyses, in vivo and in vitro cytokine, and Adrb2 gene expression results, we speculate that the β2-agonist treatment augments β2-AR signaling responses in IMs and monocytes to mediate anti-inflammatory and tissue reparative responses during RSV infection. This result is well supported by our in vitro findings of increased IL-10 levels in R848-treated BMDMs with β2AR agonism and an opposite result when β2AR-deficient BMDMs were treated with R848 (Fig. 3C, D). While we could not observe increased IL-10 cytokine levels in lung homogenates from albuterol-treated neonates at 7 dpi (Fig. 3B), multiple possibilities might explain this discrepancy in results between BMDMs and the lung. One would be the different nature of stimuli (R848 for BMDMs vs. live RSV for lung infection). Additionally, BMDMs represent a single cell type and may contribute to a robust increase in IL-10 production when stimulated with R848 together with albuterol. On the other hand, the lung has diverse types of immune and non-immune cells, and these cell types might not respond similarly to β2-AR agonism for IL-10 production during RSV infection. Further in vivo experiments are required to fully delineate the role of lung cell type in IL-10 production in response to RSV during β2-agonist treatment. Lung macrophages are mainly two types: AMs and IMs. However, few studies have characterized further subsets of lung IMs62,63. One study characterized IMs into nerve-associated macrophages (NAMs, CD11b+CD11c–CD169+ IMs) and CD169— IMs and demonstrated that NAMs are distinct from AMs and other IM subsets and co-localize with TH+ nerve fibers in the lungs, and highly express the tissue regulatory genes (M2 phenotype) under stead-state and during influenza A infection63. M1 macrophages are pro-inflammatory and damage the tissue during viral infection, whereas M2 macrophages exhibit tissue-protective function, which is crucial for resolving tissue damage and for homeostatic maintenance64,65 Our study has to yet determine if AMs, NAMs, Ly6chi monocytes, Ly6clo and/or CD64hi monocytes are involved to mediate host protection during neonatal RSV infection with β2-agonist treatment. Since our data support the idea that albuterol can enhance the expression of phagocytosis receptors (such as CD206, TLR4, CD14) for the enhanced phagocytosis of RSV viral particles and/or RSV-infected neonatal cells, it is possible that the increased number of IMs in β2-agonist-treated neonates might confer host protection via promoting phagocytic viral clearance, inflammation resolution and lung repair. In support, previous studies found RSV-induced immunopathology and disease severity is directly associated with increased viral load and pro-inflammatory cytokine production in hospitalized children66,67. One of the significant pathogenic mechanisms of RSV-induced mortality in infants is hypersecretion of mucus and formation of mucus plugs, which limit the gas exchange and lung performance of infected patients. As reported in previous studies, we also observed elevated mucus production with RSV infection in neonates35,68. Consistent with previous studies, mucus production in these RSV-infected neonates is observed with goblet cell hyperplasia and airway inflammation based on the levels of leukocyte influx and pro-inflammatory cytokines38,69,70. Notably, treatment of RSV-infected neonates with two doses of β2-agonist at 2 and 5 dpi significantly reduced the mucus secretion and goblet cell hyperplasia as judged by PAS staining of infected lung sections and the expression levels of mucus-related genes (such as Muc5ac and Gob5). Since the mRNA levels of mucus-related genes significantly decreased with β2-agonist treatment, we speculate that β2-agonist blocks the overexpression of mucin genes during RSV infection. It is possible that β2-agonist-mediated mucus suppression involves through the reduction of lung inflammation. Alternatively, β2-agonist may directly target mucus producing cells (such as goblet cells) to suppress RSV-induced mucin production. Previous clinical studies have shown that the children <4-5 years of age with RSV infection showed increased morbidity and hospital stays than the children infected with COVID-19, highlighting the unique pathogenesis of RSV in infants/children and need of neonatal infection model to understand the host defense mechanism and therapeutic target for RSV71,72. Our study may have direct translational impact for treating RSV infection in infants/children. β2-agonist (such as albuterol) inhalation is used for bronchodilation for asthma and COPD patients which allows to rapidly increase the airspace and oxygen saturation. Our findings of inhibited mucus secretion in RSV-infected lungs, together with decreased airway inflammation, endothelial breakdown and viral replication, indicate that the β2-agonist treatment may cumulatively promote the disease recovery of RSV-infected children by promoting lung ventilation, lung healing, and antiviral immunity. Although we did not find an apparent differences in pulmonary hyperreactivity between PBS- and albuterol-treated RSV-infected neonates at a later stage of age, we cannot completely rule out the possibility that β2-agonist alters RSV-induced pulmonary hyperresponsiveness during adulthood. Given that albuterol is short-acting β2-agonist and we only analyzed the lung mechanics when mice reached the age of 12-15 weeks, it is uncertain if the effect will also be the same at early stages of adult age ( < 12 weeks old) and if we use the long-acting β2-agonist (e.g., Salmeterol). Further study is needed to determine the impact of neonatal β2-agonist administration in RSV-infected neonates on the development of pulmonary hyperresponsiveness during adulthood. While our study could not fully explain why our results do not align with clinical studies regarding the efficacy of albuterol in RSV-infected infants, several factors may explain the discordant results. First, in most clinical studies, use of albuterol was initiated after the patients reached to certain stages of disease severity, for examples, after RSV-induced bronchiolitis and hospitalizations73. However, in our model, we administered albuterol to RSV-infected neonates starting at 2 dpi, a time when infected neonates do not or minimally exhibit clinical signs. There could be different impacts in RSV clearance and morbidity with early vs. late treatment of albuterol in RSV-infected patients. Second, the dose and route of albuterol administration may be critical in anti-RSV host response, as we delivered the agonist (5 µg/neonate) via the intranasal route. Our method of administration may help the agonist reach the distal alveolar region of the lung as compared to the nebulization (i.e., inhalational) route, as reported in published clinical studies74–76. To this support, some studies suggest that the β2-agonist may not consistently reach to the deep alveolar region with nebulization route of delivery75,76. Since our phenotypes with β2-agonist treatment involve an increase in IM and monocyte numbers and a reduction in lung inflammation and mucus production, the anti-RSV host response with albuterol treatment might increase with the delivery route that helps the agonist reach the distal airway region of the lung where IMs and monocytes are located. Third, we used two doses of albuterol treatment in our neonatal RSV infection model, which might explain why at least two doses of albuterol treatment (at 2 and 5 dpi) are critical for inducing anti-RSV defense. These two doses of agonist treatment is essential for suppressing pathologic airway and interstitial inflammation in RSV-infected neonates while maintaining endothelial barrier function and IFN-λ expression77. It is less likely that albuterol-treated infants in clinical studies received such combination of treatment with similar doses. Limitations of study Our study has demonstrated a previously unknown role of β2-AR signaling axis in orchestrating host protection to RSV infection in neonates. Some important questions are left to be addressed by future research. First, regarding the question about the clinical benefits of albuterol treatment is specific to our model or it could be applied more broadly to other scenario, we acknowledge future study would be needed to fully understand the generalizability of albuterol efficacy in anti-RSV response.We also believe that our study differs in many ways from clinical studies, and the results we observed may provide a proof-of-concept idea and be critical for future studies focusing on antiviral role of the β2-adrenergic signaling pathway. Second, while our study found that the local β2-AR agonist treatment in RSV-infected neonatal mice at 2 and 5 dpi decreased morbidity, viral load, barrier dysfunction, and lung pathology, we have to yet determine the clinical beneficial role of β2-agonist at later phase of infection (after 14 dpi) and also the cumulative efficacy of agonist when administer more than two doses at early and later phase of infection. Third, how does IFN-λ mediates suppression of RSV replication in neonatal lungs? There could be multiple underlying mechanisms for this. As demonstrated for the clearance of SARS-CoV2 viruses in mice, one could be through enhancing antiviral effector function of RSV-specific killer cells such as CD8+ T cells78. Upon secretion, IFN-λ might act on airway epithelial cells and thereby confers direct antiviral protection. Other mechanism might be promoting the antigen presentation abilities of migratory DC (such as CD103+ DC) for enhanced recognition of RSV-infected cells and thus viral clearance18,78. Moreover, endogenous IFN-λ signaling and intranasal administration of exogenous IFN-λ, both confer host protection against influenza and COVID-19 infection by reducing viral burden and tissue inflammation18,78–80. It might be possible that β2-AR-mediated IFN-λ enhancement in RSV infection led to both lung inflammation suppression and antiviral responses with minor involvement of ISGs in neighboring cells. Fourth, we also do not know if β2-agonist influences effector functions of CD8+ T, CD4+ T and NK cells and the quality of B cells (e.g. neutralizing antibody production) in response to RSV challenge. Following RSV infection, expansion of RSV-specific CD8+ T cells and B cells are critical for viral clearance in the lung and to protect neonates from disease severity7,9. Our results suggest that the β2-agonist administration suppresses the total numbers of B cells in airspaces and does not enhance the RSV-specific CD8+ T cells, BAL IgA level, and overall numbers of B and NK cells in the lungs. Thus, the mechanisms leading to their immunomodulation remain to be determined. Fifth, while we observed increased IMs in BAL and whole lungs at 7dpi with albuterol treatment, it is yet to be determined how β2-agonist treatment leads to increased IMs in RSV-infected lungs and if such an increase in IM number plays a role in suppressing immunopathology during RSV infection. Our current analyses do not distinguish NAMs and other subsets within IMs, so complete characterization of IM subsets and their functional gene expression using high throughput methods such as single-cell RNAseq will help determine the role of individual IM subsets in RSV infection. In our study, we relied on RSV virus stock from ATCC and had to purchase different lots to fulfill the experimental need. There could be some impact in viral infectivity and lung pathology among neonates in experiments due to the use of different lots of RSV stocks (Supplementary table 1). We also acknowledge that the initial body weight of neonates at the day of infection is essential for consistency in disease morbidity and lung pathology phenotypes among the litters/cohorts. Methods Approval All animal experiments were approved by the Institutional Animal Care and Use Committee of Kansas State University (KSU), with approval numbers 4571 and 5021. The use of the pathogen was approved by the Institutional Biosafety Committee of KSU (approval numbers: 1546, 1766). Seven-day-old (P7) and twelve-day-old (P12) neonatal mice, as well as RSV-infected adult mice, were used in the experiments. Mice C57BL/6 J and Adrb1tm1Bkk Adrb2tm1Bkk /J (described here as Adrb1–/–Adrb2–/–) mice were originally purchased from Jackson Laboratories. Adrb1–/– Adrb2–/– mice were first bred with C57BL/6 J mice to generate heterozygous mice. The Adrb2–/– mice used in the experiments were generated after multiple backcrosses in the C57BL/6 J background. Adult C57BL/6 J and Adrb2–/– mice were housed and bred in a pathogen-free animal facility at KSU. Before a week of delivery of pups, pregnant females were separated and transferred to the ABSL-II facility at KSU. Pregnant females were housed in a microisolator with 12-hour light and dark cycle, maintaining 30-70% humidity, and monitored daily for their litters until birth. Infection was carried out in postnatal day 7 (P7) pups, and the experiment was ended at the indicated time points before or at 14 dpi. For the infection in 6-OHDA-treated pups, infection was performed at P12 age. All P7 or P12 neonates from each litter were used only for 1 experiment and considered as one independent experiment. Litter of size <3 pups was not used for the experiment. Both male and female neonates in the litter were included in the study design, and data were not separated or reported based on sex. Sample collection and processing were performed in an aseptic environment. For Adrb2–/– experiments, in-house C57BL/6 J pups were used as receptor-sufficient (Adrb2+/+) groups. Virus and intranasal inoculation Human respiratory syncytial virus (RSV-A2 strain, Cat# VR-1540) used for in vivo and in vitro infection experiments was obtained from ATCC. Once the virus was received from ATCC, it was aliquoted and stored at −80 °C for infection. On the day of infection, the virus was transported to an ABSL-II facility, where it was maintained at a cold temperature (in dry ice) and then thawed immediately before intranasal inoculation. As described in our previous study28, RSV-A2 (1.6 × 106 TCID50/10 µL) was inoculated via the intranasal route into isoflurane-induced pre-anesthetized P7 or P12 neonates. Mock group neonates were intranasally inoculated with 10 µL of sterile 1X PBS. The RSV aliquots were exposed to UV for 120 seconds and were used for UV-inactivated RSV challenge experiments. The UV inactivation of RSV was confirmed by the absence of plaques in a plaque-forming assay using UV-exposed virus. Infected neonates were kept with their moms in a micro-isolator and monitored twice a day till the end point of the experiments. Compound treatment and inoculation For ablation of sympathetic neurons, neonates were intraperitoneally injected with 6-Hydroxydopamine hydrochloride (6-OHDA, Cat# H4381, Sigma-Aldrich) in 20 μL total volume (100 mg/kg in 0.1% ascorbic acid/PBS) for 4 consecutive days starting from P4 till P7. The control group of mice received vehicle (0.1% ascorbic acid/PBS) only. At the P12 stage, RSV was intranasally inoculated as described above, and the experiment was ended after 7dpi. For the treatments of albuterol (Cat# 1012600, Sigma-Aldrich) or IFN-λ2 (Cat# 250-33, Peprotech), RSV-infected neonates were intranasally inoculated with albuterol (5 μg/10 μL/neonate) or IFN-λ2 (1 μg/10 μL/neonate) at 2dpi and 5dpi. Neonates were monitored for survival and body weight until 14dpi or 7dpi for other experiments. Collection of BALF and Whole lung tissue For BALF collection, neonates were first euthanized with CO2 overdose, followed by an incision of the neck area using sterile forceps to expose the trachea and a cannula (22 G) catheter was inserted into the trachea. Next, the lung cavity was flushed twice with 250 μL of BAL buffer containing heparin (20 U/mL, Sigma-Aldrich), dextrose (1 mg/mL, Fisher Chemicals) and 1X PBS. A total volume of ~0.4 mL of BALF was collected in 1.5 mL sterile microcentrifuge tube. For the whole lung collection, the chest cavity was opened aseptically, and the lung lobes were collected in a 1.5 mL sterile microcentrifuge tube and processed for gene and protein expression level analyses or plaque assay. All samples were kept on ice until further processing or immediately stored at −80 °C. Hematoxylin and eosin (H&E) and periodic acid–Schiff (PAS) staining After 7 dpi, RSV- and mock-inoculated neonates were euthanized with CO2 exposure. The intact whole lung together with heart and trachea was isolated and kept in 10 mL of neutral buffered formalin (10%) (Sigma-Aldrich) solution at room temperature for 24 hours. The formalin fixed tissue samples were sent to Veterinary Diagnostic Laboratory, KSU for sectioning, staining, and slide scanning. Digitally scanned images of H&E and PAS-stained lung sections were processed using Aperio ImageScope software. H&E images were scored by a trained person who was blinded with samples following the previous publications with minor modifications29,81. The scored data were generated for each lobe after examining 3-4 different area of the lobe with higher magnifications (20X) images and then the scores were averaged for each mouse and the average score per mouse was plotted for graphical representation. H&E images were scored using the following criteria: Score of 0-1 (Normal/ healthy), 1-2 (Mild/minimal), 2-3 (Moderate), and 3-4 (Severe) damage as described in the supplementary table 2. BALF processing and flow cytometry analyses After collection, BALF was centrifuged at 490 g for 5 minutes at 4 °C and the pellet was resuspended in 1 mL PBS and 250 µL cell suspension (1/4th) was used for RBC analysis. The rest of the cell suspension was re-centrifuged and resuspended in RBC lysis buffer (Thermo Fisher) for 7 minutes at room temperature. Then, cells were washed with Flow buffer [1XPBS, 2% FBS (Hyclone) and 0.2 mM EDTA (RPI Research)] and centrifuged at 490 g for 5 minutes at 4 °C. Cell pellets were then resuspended with a 200 µL Flow buffer. Next, resuspended cell suspension (10 µL) were mixed in 1:20 dilution of trypan blue (0.04%) (Sigma-Aldrich) and viable cells were counted using a hemocytometer. For flow cytometry analyses, the cell suspensions were first transferred to the V-bottom plate, treated with FcR-blocking solution (Miltenyi Biotec), followed by dark incubation with antibody cocktails prepared in Flow staining buffer (1X PBS and 2% FBS) for 25 minutes on ice. Next, antibody-stained cells were centrifuged at 490 g for 5 minutes at 4 °C and then washed with Flow buffer and re-centrifuged at 490 g for 5 minutes/4 °C. Finally, stained cell pellets were resuspended with 200 µL fixative buffer (0.5 mM EDTA, 2% paraformaldehyde and 1X PBS) and were kept on ice for 25 minutes. Antibodies used for RBC experiment are listed in the Supplementary Table 3. Antibodies used for immune cell characterization are listed in the Supplementary Table 4. Positive immune cells were gated using fluorescence minus one (FMO) as a negative staining control. To exclude dead cells, Zombie Yellow (Biolegend) was used. Data was acquired in LSRII Fortessa (BD) or Northern Lights (Cytek) flow cytometer. Then, exported FCS data files were analyzed with FlowJo (Treestar, version 10.10) and the table was created for quantification of immune cells or RBCs. BAL protein and albumin measurement After collection, BALF was centrifuged at 490 g for 5 minutes at 4 °C and the supernatant was transferred to new sterile tubes. Next, protease and phosphatase inhibitor (1%, Thermo Scientific) was added to the supernatant, then aliquoted and stored at −800C until further processing. The levels of total protein in BALF were measured using BCA assay (PierceTM BCA protein assay kit) and the levels of BALF albumin were measured by albumin assay (BCG Albumin assay kit, Sigma), following manufacturer’s instructions. Furthermore, BALF IgA levels were measured using IgA ELISA (Mouse IgA ELISA Antibody Pair kit, STEMCELL Technologies) following manufacturer’s instructions. Whole lung single cell preparation and flow cytometry analyses After whole lung collection, tissue was chopped into small pieces in RPMI and then incubated at 370C with 250 rpm shaking in a digestion buffer (RPMI, 2% FBS) containing 30 µg/mL DNase I (Roche) and 1.5 mg/mL Collagenase IV (Sigma-Aldrich) for 50 minutes. Cells and smaller tissue chunks were then passed through a 28 G syringe 3X times and filtered through a 70-µm cell strainer into a prefilled RPMI tube. Next, cells were centrifuged at 490 g for 5 minutes at 4 °C and the pellet was resuspended with 1X RBC lysis buffer (ThermoFisher) for 10-12 minutes at room temperature. Cells were then washed with Flow buffer and centrifuged at 490 g for 5 minutes at 4 °C. Cell pellets were then resuspended with 1 mL Flow buffer, followed by dilution of cell suspension with trypan blue (0.04%) (Sigma-Aldrich) and viable cells were counted using a hemocytometer. For flow cytometry analyses, antibody cocktails for myeloid and lymphoid panels were prepared 10-15 minutes advance in Flow staining buffer in the separate tubes. Next, 2×106 cells/well were transferred to the V-bottom plate and treated with FcR-blocking solution (Miltenyi Biotec), followed by incubation of cells with antibody cocktails for 25 minutes in ice in dark. After incubation, antibody-stained cells were centrifuged at 490 g for 5 minutes at 4 °C and then washed with Flow buffer and re-centrifuged at 490 g for 5 minutes/4 °C. Finally, stained cell pellets were resuspended with 300 µL fixative buffer (0.5 mM EDTA, 4% paraformaldehyde and PBS) and were kept in ice in dark until data was acquired in the flow cytometer. For RSV-specific CD8 T+ cell staining, PE-conjugated RSV M282-90 tetramer was used (received from NIH Tetramer Core Facility, Emory University, Atlanta). Antibodies used for staining lung immune cells are listed in the supplementary table 5 & 6. Positive immune cell populations were determined by using FMO as a negative staining control. To exclude dead cells, LIVE/DEAD fixable aqua (Invitrogen) or Zombie Yellow (Biolegend) was used. Flow cytometry was conducted on LSRII Fortessa flow cytometer (BD) and data files were analyzed using FlowJo (Treestar, version 10.10) software. Measurement of cytokine and chemokine levels in lung tissues Immediately after the whole lung collection, lung tissues were weighed, homogenized with BB beads (Daisy Outdoor Products) in 1 mL PBS and centrifuged to collect the whole lung supernatant. On the collected supernatant, protease and phosphatase inhibitor (1%) (Thermo Scientific) was added and then aliquoted and stored at −80 °C until further processing for total protein and cytokine measurements. Cytokines/chemokines from whole lung homogenates were measured by ELISA (BioLegend & Proteintech) or LEGENDPlex assay (BioLegend), following the manufacturer’s instructions. Total lung protein was measured using the BCA assay (PierceTM BCA Protein Assay Kit) according to the manufacturer’s protocol, and cytokine/chemokine levels were normalized to tissue weight or total protein. ELISA data were obtained from the Epoch ELISA plate reader using Gen5 software, and LEGENDPlex data were obtained from the Northern Lights (Cytek) instrument and processed and analyzed using LEGENDPlex online Data Analysis software (BioLegend). Measurement of live infectious viral titers by plaque-forming assay A plaque-forming assay was performed to measure infectious viral titers (PFU) in RSV-infected neonatal lungs82. Immediately after the whole lung collection, lung tissues were weighed, homogenized with BB beads in DMEM, and centrifuged to collect the supernatant. The collected supernatant was freshly used in the assay. The supernatant was diluted, and then the diluted samples were placed over pre-cultured PBS-washed Hep2 cells (ATCC# CCL-23) in 12-well plates. After 2 hours of incubation for viral adsorption, the preheated microcrystalline overlay media was added onto the Hep2 culture and incubated for 7 days with 5% CO2 at 37 °C without disturbing the plates. On the final day, the media was gently removed from each well, washed with PBS, and the cells were fixed using Crystal Violet, Formaldehyde, and alcohol solution for 15 minutes. The fixed cells were washed with water multiple times and then dried. Plaques were counted, and representative wells were imaged with iBright FL1500 imager (Thermo Fisher) using a default iBA analysis software with universal mode and the visible crystal violet setting enabled. Mock-inoculated mice were used as a negative control (zero plaque) for the plaque assay. Immunohistochemistry (IHC) and confocal microscopy of lung lobes At the indicated time points, neonates were first euthanized with CO2 overdose. Neonatal lungs were then inflated with 4% PFA/PBS, then collected after closing the trachea with suture thread, and kept at 4oC in 4% PFA/PBS overnight. Next, lungs were washed twice in 1X PBS and transferred to a 30% sucrose (FisherChemicals) solution and kept in 40C until the tissue reached to the bottom of the tube. Lobes were separated out and tissue were embedded in optimal cutting temperature compound (Sakura Fintek) and blocks were stored at −800C until sectioning in Cryostat (Leica Biosystems). The lobes were cut into 20-μm or 60-μM thick sections and kept in slides at −800C until staining. On the first day of staining, sections were blocked in 5% normal donkey serum (NDS) and 5% normal goat serum (NGS) or 10% NDS only (for RSV staining) for 5 hours at room temperature. Then, for neuron staining, sections were incubated with primary rabbit anti-mouse TH (EMD Millipore, Catalog# EMD-AB152) and rat anti-mouse CD31 (Dianova, Catalog# DIA-310) antibodies overnight at 40C in plate rocker. For RSV staining, sections were incubated overnight at 4 °C in a plate rocker with primary goat anti-RSV (Meridian Biosciences, Cat# B65860G), rat anti-F4/80 (Abcam, Cat# Ab90247), and rabbit anti-EpCAM (Abcam, Cat# Ab282457) antibodies. After incubation, sections were washed with PBST (PBS, 0.3% Triton X-100) and incubated with appropriate secondary antibodies [donkey anti-rabbit Alexa Fluor 647 (Thermo Fisher), goat anti-rat Alexa Fluor 594 (Abcam), donkey anti-goat Alexa Fluor 633 (Thermo Fisher), donkey anti-rabbit Alexa Fluor plus 555 (Thermo Fisher), and donkey anti-rat Alexa Fluor 488 (Thermo Fisher)], for 3 hours at room temperature. After the incubation, sections were washed in 1X PBS and mounted on slides using Vecta Shield (Vector laboratories) containing DAPI (2 µg/mL, Sigma). All antibodies used in IHC are listed in the supplementary table 7. Stained sections in slides were kept in dark and stored at 40C until microscopy. A laser scanning microscope (LSM 880 Airyscan, Zeiss) was used to capture images of the sections with Z-stacks and tiling, or Z-stacks only for RSV staining. Once the images were acquired, they were processed in Zen software (Zeiss) for maximum intensity projection and addition of scale bars. For creating 3D movies, FIJI software was used. Isolation and culture of adult and neonatal bone marrow-derived macrophages (BMDMs) Adult (8-week-old) and neonatal (P14) mice were first euthanized by using CO2 overdose. Then, muscles were separated to get the limb bones (tibias and femurs) and washed with sterile 1X PBS containing 2% FBS. Bones were then crushed using a sterile mortar and pestle with sterile 1X PBS containing 2% FBS to release bone marrow (BM) cells. The BM cell suspension was passed through a 70-μM cell strainer (Cell Treat Scientific) and cells were incubated with 1X RBC lysis buffer at room temperature for 8-11 minutes, followed by washing of cells twice with 1X PBS containing 2% FBS and centrifuging at 490 g for 5 minutes/4oC to get the cell pellet. Next, the cell pellets were suspended in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS. Approximately 10 ×106 BM cells from adult mice and 5 ×106 BM cells from P14 mice were cultured at 37 °C with 5% CO2 in Petri dishes with 10 mL of conditioned DMEM (cDMEM) media containing 20% FBS, 30% L929 cell culture supernatant and 1% antibiotic-antimycotic solution (Gibco). On day three of incubation, an additional 10 mL cDMEM was added to the cultured cells and incubated at 37 °C. On day six or seven, supernatant was removed from the dishes and differentiated BMDMs were dislodged with ice-cold 2.5 mM EDTA/PBS solution and cells were collected in DMEM containing 10% FBS. Cell suspension was centrifuged at 490 g for 5 minutes at 4oC and cell pellets were resuspended with 2 mL of DMEM/10% FBS for cell counting and were used for seeding into 96-well plates. In vitro stimulation of BMDMs and cytokine measurement For cytokine measurement, 1.5 × 105 adult or neonatal BMDMs were first seeded into flat-bottomed 96-well plates in DMEM containing 10% FBS and incubated at 37 °C overnight with 5% CO2. Cells were then washed with warm 1X PBS and co-treated with R848 (Cat# tlrl-r848-1, Invivogen) together with PBS, albuterol or xamoterol (Cat# 0950, Tocris) for 8 hours. Cells were centrifuged at 490 g for 5 minutes/4oC and supernatant was stored at −80 °C until the cytokine measurement. The levels of cytokines and chemokines were measured by ELISA (BioLegend) as per manufacturer’s instructions. For the measurement of expression levels of phagocytosis receptors, 2 × 105 neonatal BMDMs were first seeded into flat-bottomed 96-well plates in DMEM containing 10% FBS and incubated with 5% CO2 at 37 °C overnight. Cells were then washed with warm sterile 1X PBS and infected with live RSV-A2 (Cat# VR1540-P, ATCC) together with PBS or albuterol for 4 hours. Cells were then washed with warm PBS and lysed directly in the wells using Trizol, and lysates were stored at −80 °C until the RNA was isolated. Gene expression and viral load measurement Whole lung samples were homogenized with sterile BB beads (Daisy Outdoor) in 1 mL Trizol reagent (Invitrogen) using TissueLyser II (Qiagen). RNA was isolated using PureLinkTM RNeasy Mini Kit (Thermo Fisher Scientific). To minimize DNAse contamination, in-column PureLinkTM DNAse (Invitrogen) treatment protocol was followed as recommended by the manufacturer. Then, RNA was reverse-transcribed to cDNA using SuperScript II cDNA Synthesis Kit (Invitrogen) after treatment with RNAseOUT (Invitrogen). The relative gene expression was determined by quantitative PCR on ABI 7000 System (Applied Biosystems) using PowerUpTM SYBR Green Master Mix (Applied Biosystems). Primers used for gene expression analysis were used in previous studies and are listed in supplementary table 8. The mRNA level of each gene was normalized to the expression of Gapdh. The normalized mRNA expression levels were presented as a fold change difference using the ΔΔCt method. For heatmap generation, we used mean of the fold changes of the group. For viral load measurement, the levels of RSV N & RSV L viral RNA were quantified using a standard curve that determines the absolute copy number of viral RNA. A standard curve was generated using quantitative RSV genomic RNA (VR-1540DQ, ATCC). The sample was serially diluted 2-fold and 10-fold. The detected Ct values were plotted to create a standard curve. Undetermined values were considered as absence of copy number and were used as zero in analyses. For phagocytosis receptor gene expression analyses, BMDM RNA was isolated using PureLinkTM RNeasy Mini Kit (Thermo Fisher Scientific) and quantified. Then, RNA was reverse-transcribed to cDNA using the SuperScript II cDNA Synthesis Kit (Invitrogen). The relative gene expression was determined using quantitative PCR with the QuantStudio-3 (ThermoFisher) and PowerUp SYBR Green Master Mix (Applied Biosystems). The primers used in this experiment were previously used and are listed in supplementary table 8. The mRNA level of each gene was normalized to the expression of Gapdh. For viral RNA measurement, the sample was serially diluted 10-fold. The levels of RSV N viral RNA were quantified using a standard curve method to determine the absolute copy number of viral RNA as discussed above. Pulmonary hyperresponsiveness measurement Neonatal mice were inoculated with RSV or mock at seven days of their birth, followed by albuterol or PBS treatment intranasally at 2 and 5 days post-inoculation. Lung mechanics were measured to determine pulmonary hyperresponsiveness in all cohorts of mice (12-15 weeks old) using a Flexivent (SCIREQ). For this, each mouse was first anesthetized by inhalation of 3-4% isoflurane, followed by a tracheostomy using a 22 G cannula and connection to the Flexivent. All mice were ventilated at 150 Hz, with a tidal volume of 10 mL/Kg, and a positive end-expiratory pressure level of 300 mm H2O. The nebulizer was used for 10 seconds to administer saline (0.9% NaCl) or methacholine chloride (MCh, Methapharm). For each mouse, the baseline (0 mg/mL MCh) measurement was first performed using saline only, followed by measurement with exposure of 6.25 mg/mL MCh (dissolved in 0.9% NaCl). The following lung mechanical parameters were measured: Rrs, Ers, Rn, and G. Rrs measurements provide the information of total airway constriction, whereas Ers provide information about total airway stiffness, Rn about central airway constriction, and G about small and alveolar tissue constriction. Data files were acquired with the Flexiware software (Version 8), and all data were then analyzed and graphed in Prism. Statistical analysis Sample size and statistical details are described in figure legends and source data file. All statistical analyses were performed using GraphPad Prism 10 software. Data were tested for normality and differences in variance was used to apply appropriate statistical test (parametric or non-parametric). Mean differences of two experimental groups were compared using either a one-tailed, two-tailed unpaired t-test or Mann-Whitney test. Means of more than two groups were analyzed using One-way ANOVA, Brown-Forsythe and Welch ANOVA, Two-way repeated measure ANOVA and Kruskal-Wallis test. Fisher’s test, uncorrected Dunn’s test, Dunn’s multiple comparisons test, and Sidak’s test for post hoc analysis were performed as indicated in each figure legend. Mean differences between experimental groups were represented as follow: not significant (ns), *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data representation and visualization For heatmaps, data generated from RT-qPCR experiments were normalized and averaged. All averaged data were plotted to generate a heatmap using Morpheus software (Broad Institute). BioRender (http://biorender.com) was used to create schematic. All generated representations, graphs and schematics from PRISM, Morpheus, FlowJo and BioRender were aligned and finalized for figures in Adobe Illustrator (Adobe Inc.). Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supplementary information Description of Additional Supplementary Files Supplementary video 1 Supplementary video 2 Supplementary video 3 Reporting Summary Transparent Peer Review file Supplementary information Description of Additional Supplementary Files Supplementary video 1 Supplementary video 2 Supplementary video 3 Reporting Summary Transparent Peer Review file Source data Source data Source data